WEGNER CPAS LLP 2921 LANDMARK PL STE 300 MADISON, WI 53713-4236

> HEMOSTASIS AND THROMBOSIS RESEARCH SOCIETY, INC. 8733 WATERTOWN PLANK ROAD MILWAUKEE, WI 53226-3548

hhimiliadahhiliadahiliadahiliadahili

	000	
Form	770	

# \*\* PUBLIC DISCLOSURE COPY \*\* Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations) Do not enter social security numbers on this form as it may be made public. Go to www.irs.gov/Form990 for instructions and the latest information. OMB No. 1545-0047

Department of the Treasury Internal Revenue Service

Т

A For the 2022 calendar year, or tax year beginning and ending										
В	Check if	C Name of organization		D Employer identific	ation number					
i	applicat	HEMOSTASIS AND THROMBOSIS RESEARCH								
	Addr chan	SOCIETY, INC.								
	Name Doing business as 39-1796672									
	Initia retur	Number and street (or P.O. box if mail is not delivered to street address)	Room/suite	E Telephone number						
	Final retur	8733 WATERTOWN PLANK ROAD		414-937-0	5569					
	termi ated			<b>G</b> Gross receipts \$	1,771,378.					
	Ame retur	MATTWATTER WT 53226-3548		H(a) Is this a group re	turn					
	Appl tion	F name and address of principal officer: DORIDIN ORCODSEN = 1E	EWS	for subordinates						
	pend	SAME AS C ABOVE		H(b) Are all subordinates in						
1	Tax-e	empt status: 🔀 501(c)(3) 🗌 501(c) ( ) (insert no.) 🗌 4947(a)(1) d	or 🗌 527	1	list. See instructions					
J	Webs	ite: WWW.HTRS.ORG		H(c) Group exemption	n number					
ĸ	Form o	f organization; 🚺 Corporation 🔄 Trust 🔄 Association 📄 Other	L Year of	of formation: 1994 N	State of legal domicile: WI					
Pa	art I	Summary								
	1	Briefly describe the organization's mission or most significant activities: TO BI	E THE I	LEADING NONE	ROFIT					
nce		PROFESSIONAL SOCIETY IN NORTH AMERICA DED								
Governance	2	Check this box if the organization discontinued its operations or dispos	ed of more	than 25% of its net ass	ets.					
Nel	3	Number of voting members of the governing body (Part VI, line 1a)		3	15					
		Number of independent voting members of the governing body (Part VI, line 1b)		4	15					
00 00	5	Total number of individuals employed in calendar year 2022 (Part V, line 2a)		5	0					
/itie	6	Total number of volunteers (estimate if necessary)			213					
Activities &	7 a	Total unrelated business revenue from Part VIII, column (C), line 12			0.					
_	b	Net unrelated business taxable income from Form 990-T, Part I, line 11			0.					
				Prior Year	Current Year					
ð	8	Contributions and grants (Part VIII, line 1h)		1,404,188.	1,307,516.					
ňu	9	Program service revenue (Part VIII, line 2g)		143,331.	424,664.					
Revenue	10	Investment income (Part VIII, column (A), lines 3, 4, and 7d)		35,262.	39,198.					
<u>م</u>	11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)		0.	0.					
	12	Total revenue - add lines 8 through 11 (must equal Part VIII, column (A), line 12)		1,582,781.	1,771,378.					
	13	Grants and similar amounts paid (Part IX, column (A), lines 1-3)		717,882.	946,057.					
	14	Benefits paid to or for members (Part IX, column (A), line 4)		0.	0.					
ŝ	15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5-10)		305,325.	250,225.					
nse	16a	Professional fundraising fees (Part IX, column (A), line 11e)		0.	0.					
Expenses	. b	Total fundraising expenses (Part IX, column (D), line 25)	27.							
Ш	1 11	Other expenses (Part IX, column (A), lines 11a-11d, 11f-24e)		738,495.	618,326.					
	18	Total expenses. Add lines 13-17 (must equal Part IX, column (A), line 25)		1,761,702.	1,814,608.					
	19	Revenue less expenses. Subtract line 18 from line 12		-178,921.	-43,230.					
0 C			Be	ginning of Current Year	End of Year					
Net Assets or	20	Total assets (Part X, line 16)		4,175,317.	4,139,914.					
tAs	21	Total liabilities (Part X, line 26)		225,993.	405,637.					
ERe	22	Net assets or fund balances. Subtract line 21 from line 20		3,949,324.	3,734,277.					
Pa	art II									
Unc	ler pen	alties of perjury, I declare that I have examined this return, including accompanying schedules	s and stateme	ents, and to the best of my	knowledge and belief, it is					

true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign	Signature of officer	Date	Date							
-	LYNN MALEC, MD, MSC, TREAS									
	Type or print name and title									
	Print/Type preparer's name	Preparer's signature	Date Check	PTIN						
Paid	SCOTT HAUMERSEN, CPA	SCOTT HAUMERSEN, CPA		200084908						
Preparer	Firm's name WEGNER CPAS LLP		Firm's EIN 39-0	)974031						
Use Only	Firm's address 2921 LANDMARK PL									
MADISON, WI 53713-4236 Phone no. (608) 2										
May the IF	May the IRS discuss this return with the preparer shown above? See instructions									
232001 12-1	12-13-22       LHA       For Paperwork Reduction Act Notice, see the separate instructions.       Form 990 (2022)									

SEE SCHEDULE O FOR ORGANIZATION MISSION STATEMENT CONTINUATION

<ul> <li>If "Yes," describe these changes on Schedule O.</li> <li>Describe the organization's program service accomplishments for each of its three largest program services, as measured l Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total revenue, if any, for each program service reported.</li> </ul>	ARCH, ATION FOR TION FOR Yes X No by expenses. A expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>Briefly describe the organization's mission: <u>THE HEMOSTASIS AND THROMBOSIS RESEARCH SOCIETY, INC. (HTRS) IS</u> <u>LEADING NORTH AMERICAN PROFESSIONAL SOCIETY DEDICATED TO RESEA</u> <u>MENTORING, WORKFORCE DEVELOPMENT, AND CONTINUING MEDICAL EDUCA</u> <u>PHYSICIANS, INVESTIGATORS, AND ALL HEALTH CARE PROFESSIONALS</u> </li> <li>Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? If "Yes," describe these new services on Schedule O.     </li> <li>Did the organization cease conducting, or make significant changes in how it conducts, any program services, as measured I Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total revenue, if any, for each program service reported.     </li> <li>(code:) (Expenses <u>1,046,832.</u> including grants of <u>932,763.</u>) (Revenue <u>5</u> GRANTS AND ASSISTANCE: A PRIMARY STRATEGIC OBJECTIVE OF HTRS COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPO</li></ul>	S THE ARCH, ATION FOR Yes X No by expenses. al expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>THE HEMOSTASIS AND THROMBOSIS RESEARCH SOCIETY, INC. (HTRS) IS</li> <li>LEADING NORTH AMERICAN PROFESSIONAL SOCIETY DEDICATED TO RESEA</li> <li>MENTORING, WORKFORCE DEVELOPMENT, AND CONTINUING MEDICAL EDUCA</li> <li>PHYSICIANS, INVESTIGATORS, AND ALL HEALTH CARE PROFESSIONALS</li> <li>Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ?</li> <li>If "Yes," describe these new services on Schedule O.</li> <li>Did the organization cease conducting, or make significant changes in how it conducts, any program services?</li> <li>If "Yes," describe these changes on Schedule O.</li> <li>Describe the organization's program service accomplishments for each of its three largest program services, as measured I Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total revenue, if any, for each program service reported.</li> <li>(Code:</li></ul>	ARCH, ATION FOR TION FOR Yes X No by expenses. A expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
LEADING NORTH AMERICAN PROFESSIONAL SOCIETY DEDICATED TO RESEA         MENTORING, WORKFORCE DEVELOPMENT, AND CONTINUING MEDICAL EDUCA         PHYSICIANS, INVESTIGATORS, AND ALL HEALTH CARE PROFESSIONALS         2       Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-E2?         If "Yes," describe these new services on Schedule O.         3       Did the organization cease conducting, or make significant changes in how it conducts, any program services?         If "Yes," describe these changes on Schedule O.         4       Describe the organization's program service accomplishments for each of its three largest program services, as measured I section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total revenue, if any, for each program service reported.         4a       (Code:) (Expenses \$ 1,046,832. including grants of \$ 932,763. ) (Revenue \$ GRANTS AND ASSISTANCE: A PRIMARY STRATEGIC OBJECTIVE OF HTRS COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPOCE	ARCH, ATION FOR TION FOR Yes X No by expenses. A expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>MENTORING, WORKFORCE DEVELOPMENT, AND CONTINUING MEDICAL EDUCA PHYSICIANS, INVESTIGATORS, AND ALL HEALTH CARE PROFESSIONALS</li> <li>Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ?</li> <li>If "Yes," describe these new services on Schedule O.</li> <li>Did the organization cease conducting, or make significant changes in how it conducts, any program services?</li></ul>	ATION FOR Yes X No by expenses. al expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>PHYSICIANS, INVESTIGATORS, AND ALL HEALTH CARE PROFESSIONALS</li> <li>Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ?</li> <li>If "Yes," describe these new services on Schedule O.</li> <li>Did the organization cease conducting, or make significant changes in how it conducts, any program services?</li></ul>	Yes X No Yes X No by expenses. a expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>PHYSICIANS, INVESTIGATORS, AND ALL HEALTH CARE PROFESSIONALS</li> <li>Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ?</li> <li>If "Yes," describe these new services on Schedule O.</li> <li>Did the organization cease conducting, or make significant changes in how it conducts, any program services?</li></ul>	Yes X No Yes X No by expenses. a expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ?</li> <li>If "Yes," describe these new services on Schedule O.</li> <li>3 Did the organization cease conducting, or make significant changes in how it conducts, any program services?</li></ul>	Yes X No by expenses. al expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>prior Form 990 or 990-EZ?</li> <li>If "Yes," describe these new services on Schedule O.</li> <li>3 Did the organization cease conducting, or make significant changes in how it conducts, any program services?</li> <li>If "Yes," describe these changes on Schedule O.</li> <li>4 Describe the organization's program service accomplishments for each of its three largest program services, as measured to section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total revenue, if any, for each program service reported.</li> <li>4a (Code:) (Expenses \$ 1,046,832. including grants of \$ 932,763. ) (Revenue \$ GRANTS AND ASSISTANCE: A PRIMARY STRATEGIC OBJECTIVE OF HTRS COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPOCE</li> </ul>	Yes X No by expenses. al expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>If "Yes," describe these new services on Schedule O.</li> <li>Did the organization cease conducting, or make significant changes in how it conducts, any program services? If "Yes," describe these changes on Schedule O.</li> <li>Describe the organization's program service accomplishments for each of its three largest program services, as measured to Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total revenue, if any, for each program service reported.</li> <li>(Code:) (Expenses \$1,046,832including grants of \$932,763) (Revenue \$</li></ul>	Yes X No by expenses. al expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>3 Did the organization cease conducting, or make significant changes in how it conducts, any program services?</li></ul>	by expenses. al expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>If "Yes," describe these changes on Schedule O.</li> <li>Describe the organization's program service accomplishments for each of its three largest program services, as measured it Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total revenue, if any, for each program service reported.</li> <li>(code:) (Expenses \$1,046,832. including grants of \$932,763. ) (Revenue \$</li> <li>GRANTS AND ASSISTANCE: A PRIMARY STRATEGIC OBJECTIVE OF HTRS COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPORE</li> </ul>	by expenses. al expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>4 Describe the organization's program service accomplishments for each of its three largest program services, as measured the Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total revenue, if any, for each program service reported.</li> <li>4a (code:) (Expenses \$1,046,832. including grants of \$932,763. ) (Revenue \$ GRANTS AND ASSISTANCE: A PRIMARY STRATEGIC OBJECTIVE OF HTRS COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPORE</li> </ul>	al expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
<ul> <li>Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total revenue, if any, for each program service reported.</li> <li>4a (code:) (Expenses \$1,046,832. including grants of \$932,763.) (Revenue \$</li> <li>GRANTS AND ASSISTANCE: A PRIMARY STRATEGIC OBJECTIVE OF HTRS COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPORT</li> </ul>	al expenses, and 313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
revenue, if any, for each program service reported. 4a (Code:)(Expenses \$ 1,046,832. including grants of \$ 932,763.) (Revenue \$ GRANTS AND ASSISTANCE: A PRIMARY STRATEGIC OBJECTIVE OF HTRS COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPO	313,479. IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
4a (Code:)(Expenses \$1,046,832. including grants of \$932,763.) (Revenue \$ GRANTS AND ASSISTANCE: A PRIMARY STRATEGIC OBJECTIVE OF HTRS COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPO	IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
GRANTS AND ASSISTANCE: A PRIMARY STRATEGIC OBJECTIVE OF HTRS COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPO	IS TO AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
COMBAT THE CRITICAL SHORTAGE OF SKILLED PHYSICIAN-SCIENTISTS A DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPO	AND S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
DISCOVERY-BASED RESEARCHERS DEDICATED TO CAREERS IN HEMOSTASIS THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPO	S AND ORTUNITY ERS GRANTS OR THIS DEPENDENT
THROMBOSIS IN NORTH AMERICA BY PROVIDING MEMBERS WITH THE OPPO	ORTUNITY ERS GRANTS OR THIS DEPENDENT
	ERS GRANTS OR THIS DEPENDENT
TO APPLY FOR INVESTIGATOR-INTTIATED RESEARCH GRANTS. HTRS OFFI	OR THIS DEPENDENT
	DEPENDENT
THROUGH THE PROGRAMS OUTLINED BELOW, USING FUNDS RESTRICTED FO	
PURPOSE AND RAISED FROM PHARMACEUTICAL COMPANIES VIA THEIR INI	
MEDICAL EDUCATION (IME) GRANT PROGRAMS OR CORPORATE PHILANTHRO	
FORM OF EDUCATIONAL EVENT OR EXHIBIT SPONSORSHIP. HTRS RESEARC	
SUPPORT PHYSICIAN-SCIENTISTS (I.E. ACADEMIC MEDICAL RESEARCHEF	RS WITH
MDS, DOS, AND MD/PHDS) AND DISCOVERY-BASED SCIENTISTS (I.E.	
	T CRITICAL
4b (Code:) (Expenses \$393,633.         including grants of \$13,294.         (Revenue \$)	111,185.
EDUCATION: HTRS OFFERED THE FOLLOWING PROGRAMS IN FY 2022 TO S	
THE PROFESSIONAL EDUCATION AND CAREER DEVELOPMENT OF OUR MEMBE	ERS: TWO
(2) IN-PERSON TRAINEE WORKSHOPS FOR MEDICAL RESIDENTS AND FELI	LOWS
INTERESTED IN BUILDING A CAREER IN HEMOSTASIS AND THROMBOSIS;	TWO (2)
CONECCTOR MEETINGS FOR JUNIOR FACULTY WHO RECENTLY LAUNCHED TH	HEIR
ACADEMIC RESEARCH CAREERS (MDS, DOS, PHDS); TWO (2) HTRS AND (	
"BEST OF" ABSTRACT REVIEW AND NETWORKING EVENTS, SPONSORED BY	
GENENTECH, THE FIRST HELD DURING THE THSNA 2022 SUMMIT IN CHIC	CAGO, IL,
AND THE SECOND DURING THE 2022 AMERICAN SOCIETY FOR HEMATOLOGY	Y (ASH)
NATIONAL CONGRESS IN NEW ORLEANS, LA; AND TWO (2) HTRS FELLOWS	S NETWORK
MEMBER MATCH EVENTS, DESIGNED TO INTRODUCE TRAINEES TO MORE EX	XPERIENCED
HTRS MEMBERS WHO HAVE AN INTEREST IN MENTORING; THESE EVENTS W	WERE ALSO
4c         (Code:) (Expenses \$ including grants of \$) (Revenue \$)	
4d Other program services (Describe on Schedule O.)	
	)
(Expenses \$ including grants of \$ ) (Revenue \$ 4e Total program service expenses 1,440,465.	)
4e   Total program service expenses   1,440,465.	Form <b>990</b> (202
SEE SCHEDULE O FOR CONTINUATION(S)	Form 330 (202
3 )905 788028 13399.1AS01 2022.04020 HEMOSTASIS AND THRO	

SOCIETY, INC.

Part IV Checklist of Required Schedules

Form 990 (2022)

			Yes	No
1	Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)?			
	If "Yes," complete Schedule A	1	X	
2	Is the organization required to complete Schedule B, Schedule of Contributors? See instructions	2	Х	
3	Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for			
	public office? If "Yes," complete Schedule C, Part I	3		_X
4	Section 501(c)(3) organizations. Did the organization engage in lobbying activities, or have a section 501(h) election in effect			
	during the tax year? If "Yes," complete Schedule C, Part II	4		_X
5	Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or			
_	similar amounts as defined in Rev. Proc. 98-19? If "Yes," complete Schedule C, Part III	5		<u> </u>
6	Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to			37
_	provide advice on the distribution or investment of amounts in such funds or accounts? If "Yes," complete Schedule D, Part I	6		<u> </u>
7	Did the organization receive or hold a conservation easement, including easements to preserve open space,			77
_	the environment, historic land areas, or historic structures? If "Yes," complete Schedule D, Part II	7		<u> </u>
8	Did the organization maintain collections of works of art, historical treasures, or other similar assets? If "Yes," complete			v
-	Schedule D, Part III	8		<u> </u>
9	Did the organization report an amount in Part X, line 21, for escrow or custodial account liability, serve as a custodian for			
	amounts not listed in Part X; or provide credit counseling, debt management, credit repair, or debt negotiation services?			х
10	If "Yes," complete Schedule D, Part IV	9		
10	Did the organization, directly or through a related organization, hold assets in donor-restricted endowments		х	
	or in quasi endowments? If "Yes," complete Schedule D, Part V	10	~	
11	If the organization's answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X,			
_	as applicable.			
а	Did the organization report an amount for land, buildings, and equipment in Part X, line 10? If "Yes," complete Schedule D,	44.		х
b	Part VI Did the organization report an amount for investments - other securities in Part X, line 12, that is 5% or more of its total	<u>11a</u>		
U	assets reported in Part X, line 16? If "Yes," complete Schedule D, Part VII	11b		х
~	Did the organization report an amount for investments - program related in Part X, line 13, that is 5% or more of its total			
C	assets reported in Part X, line 16? If "Yes," complete Schedule D, Part VIII	11c		х
Ь	Did the organization report an amount for other assets in Part X, line 15, that is 5% or more of its total assets reported in			
u	Part X, line 16? If "Yes," complete Schedule D, Part IX	11d		х
<u>م</u>	Did the organization report an amount for other liabilities in Part X, line 25? If "Yes," complete Schedule D, Part X	11e		X
f	Did the organization's separate or consolidated financial statements for the tax year include a footnote that addresses	110		
•	the organization's liability for uncertain tax positions under FIN 48 (ASC 740)? <i>If</i> "Yes," <i>complete Schedule D, Part X</i>	11f		х
12a	Did the organization obtain separate, independent audited financial statements for the tax year? If "Yes," complete			
124	Schedule D, Parts XI and XII	12a	х	
ь	Was the organization included in consolidated, independent audited financial statements for the tax year?			
	If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional	12b		х
13	Is the organization a school described in section 170(b)(1)(A)(ii)? If "Yes," complete Schedule E	13		X
14a	Did the organization maintain an office, employees, or agents outside of the United States?	14a		Х
b	Did the organization have aggregate revenues or expenses of more than \$10,000 from grantmaking, fundraising, business,			
	investment, and program service activities outside the United States, or aggregate foreign investments valued at \$100,000			
	or more? If "Yes," complete Schedule F, Parts I and IV	14b		Х
15	Did the organization report on Part IX, column (A), line 3, more than \$5,000 of grants or other assistance to or for any			
	foreign organization? If "Yes," complete Schedule F, Parts II and IV	15		Х
16	Did the organization report on Part IX, column (A), line 3, more than \$5,000 of aggregate grants or other assistance to			
	or for foreign individuals? If "Yes," complete Schedule F, Parts III and IV	16		Х
17	Did the organization report a total of more than \$15,000 of expenses for professional fundraising services on Part IX,			
	column (A), lines 6 and 11e? If "Yes," complete Schedule G, Part I. See instructions	17		X
18	Did the organization report more than \$15,000 total of fundraising event gross income and contributions on Part VIII, lines			
	1c and 8a? If "Yes," complete Schedule G, Part II	18		X
19	Did the organization report more than \$15,000 of gross income from gaming activities on Part VIII, line 9a? If "Yes,"			
	complete Schedule G, Part III	19		X
20a	Did the organization operate one or more hospital facilities? If "Yes," complete Schedule H	20a		X
b	If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?	20b		
21	Did the organization report more than \$5,000 of grants or other assistance to any domestic organization or			
	domestic government on Part IX, column (A), line 1? If "Yes." complete Schedule I. Parts I and II	21	X	
232003	12-13-22	Form	990	(2022)

232003 12-13-22

16000905 788028 13399.1AS01

2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

4

	<u>990 (2022)</u> SOCIETY, INC. 39-1796	5672	Р	age <b>4</b>
Par	t IV Checklist of Required Schedules (continued)			
			Yes	No
22	Did the organization report more than \$5,000 of grants or other assistance to or for domestic individuals on			
	Part IX, column (A), line 2? If "Yes," complete Schedule I, Parts I and III	22	Х	
23	Did the organization answer "Yes" to Part VII, Section A, line 3, 4, or 5, about compensation of the organization's current			
	and former officers, directors, trustees, key employees, and highest compensated employees? If "Yes," complete			
	Schedule J	23		X
24a	Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than \$100,000 as of the			
	last day of the year, that was issued after December 31, 2002? If "Yes," answer lines 24b through 24d and complete			
	Schedule K. If "No," go to line 25a	24a		X
b	Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?	24b		
с	Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease			
	any tax-exempt bonds?	24c		
d	Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?	24d		
25a	Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations. Did the organization engage in an excess benefit			
	transaction with a disqualified person during the year? If "Yes." complete Schedule L. Part I	25a		X
b	Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and			
	that the transaction has not been reported on any of the organization's prior Forms 990 or 990 EZ? If "Yes," complete			
	Schedule L, Part I	25b		X
26	Did the organization report any amount on Part X, line 5 or 22, for receivables from or payables to any current			
	or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35%			
	controlled entity or family member of any of these persons? If "Yes," complete Schedule L, Part II	26		X
27	Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee,			
	creator or founder, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled			
	entity (including an employee thereof) or family member of any of these persons? If "Yes," complete Schedule L, Part III	27		X
28	Was the organization a party to a business transaction with one of the following parties (see the Schedule L, Part IV,			
	instructions for applicable filing thresholds, conditions, and exceptions):			
а	A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor? If			
	"Yes," complete Schedule L, Part IV	28a		X
b	A family member of any individual described in line 28a? If "Yes," complete Schedule L, Part IV	28b		X
с	A 35% controlled entity of one or more individuals and/or organizations described in line 28a or 28b? If			
	"Yes," complete Schedule L, Part IV	28c		X X
29	Did the organization receive more than \$25,000 in non-cash contributions? If "Yes," complete Schedule M	29		X
30	Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation			
	contributions? If "Yes," complete Schedule M	30		
31	Did the organization liquidate, terminate, or dissolve and cease operations? If "Yes," complete Schedule N, Part I	31		X
32	Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? If "Yes," complete			
	Schedule N, Part II	32		<u> </u>
33	Did the organization own 100% of an entity disregarded as separate from the organization under Regulations			
	sections 301.7701-2 and 301.7701-3? If "Yes," complete Schedule R, Part I	33		X X
34	Was the organization related to any tax-exempt or taxable entity? If "Yes," complete Schedule R, Part II, III, or IV, and			- v
05	Part V, line 1	34		X X
	Did the organization have a controlled entity within the meaning of section 512(b)(13)?	35a		
a	If "Yes" to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of paction 512(b)(12)2 (cline and controlled entity of the control of the c	35b		
26	within the meaning of section 512(b)(13)? <i>If</i> "Yes," <i>complete Schedule R, Part V, line 2</i>	350		<u> </u>
36		36		x
37	<i>If</i> "Yes," <i>complete Schedule R, Part V, line 2</i> Did the organization conduct more than 5% of its activities through an entity that is not a related organization	- 50		<u> </u>
57	and that is treated as a partnership for federal income tax purposes? If "Yes," complete Schedule R, Part VI	37		x
38	Did the organization complete Schedule O and provide explanations on Schedule O for Part VI, lines 11b and 19?			<u> </u>
00		38	х	
Par		1 00		<u> </u>
	Check if Schedule O contains a response or note to any line in this Part V			X
			Yes	
1a	Enter the number reported in box 3 of Form 1096. Enter -0- if not applicable 1a 28	3		
b	Enter the number of Forms W-2G included on line 1a. Enter -0- if not applicable 1b	_		
	Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming			
	(gambling) winnings to prize winners?	1c		
232004	↓ 12-13-22	Form	990	(2022)

232004 12-13-22

16000905 788028 13399.1AS01

2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

5

39-1796672	Page 5
------------	--------

Form	990 (2022) SOCIETY, INC. 39-179	6672	Page 5					
Par	t V Statements Regarding Other IRS Filings and Tax Compliance (continued)							
			Yes No					
2a	Enter the number of employees reported on Form W-3, Transmittal of Wage and Tax Statements,							
	filed for the calendar year ending with or within the year covered by this return	<u>ן</u>						
b	If at least one is reported on line 2a, did the organization file all required federal employment tax returns?							
	Did the organization have unrelated business gross income of \$1,000 or more during the year?	3a	<u> </u>					
b	If "Yes," has it filed a Form 990-T for this year? If "No" to line 3b, provide an explanation on Schedule O	3b						
4a	At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a							
	financial account in a foreign country (such as a bank account, securities account, or other financial account)?	4a	X					
b	If "Yes," enter the name of the foreign country							
	See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).							
	Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?	<u>5a</u>						
	Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?	5b	<u> </u>					
	If "Yes" to line 5a or 5b, did the organization file Form 8886-T?	<u>5c</u>						
6a	Does the organization have annual gross receipts that are normally greater than \$100,000, and did the organization solicit							
	any contributions that were not tax deductible as charitable contributions?	<u>6a</u>	<u> </u>					
b	If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts							
	were not tax deductible?	6b						
7	Organizations that may receive deductible contributions under section 170(c).							
а	Did the organization receive a payment in excess of \$75 made partly as a contribution and partly for goods and services provided to the payor?	7a	X					
	If "Yes," did the organization notify the donor of the value of the goods or services provided?	7b						
с	Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required							
	to file Form 8282?	7c	X					
	If "Yes," indicate the number of Forms 8282 filed during the year 7d	_						
е	Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?	7e	<u>X</u>					
f	Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?	7f	<u> </u>					
-	If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?	7g						
h	If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?	7h						
8	Sponsoring organizations maintaining donor advised funds. Did a donor advised fund maintained by the							
	sponsoring organization have excess business holdings at any time during the year?	8						
9	Sponsoring organizations maintaining donor advised funds.							
а	Did the sponsoring organization make any taxable distributions under section 4966?	9a						
b	Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?	9b						
10	Section 501(c)(7) organizations. Enter:							
	Initiation fees and capital contributions included on Part VIII, line 12	_						
	Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities 10b	_						
	Section 501(c)(12) organizations. Enter:							
	Gross income from members or shareholders 11a	_						
b	Gross income from other sources. (Do not net amounts due or paid to other sources against							
	amounts due or received from them.)	_						
	Section 4947(a)(1) non-exempt charitable trusts. Is the organization filing Form 990 in lieu of Form 1041?	12a						
	If "Yes," enter the amount of tax-exempt interest received or accrued during the year	-						
13	Section 501(c)(29) qualified nonprofit health insurance issuers.							
а	Is the organization licensed to issue qualified health plans in more than one state?	13a						
	Note: See the instructions for additional information the organization must report on Schedule O.							
b	Enter the amount of reserves the organization is required to maintain by the states in which the							
	organization is licensed to issue qualified health plans	-						
	Enter the amount of reserves on hand		v					
	Did the organization receive any payments for indoor tanning services during the tax year?	14a 14b	<u> </u>					
	<b>b</b> If "Yes," has it filed a Form 720 to report these payments? <i>If "No," provide an explanation on Schedule O</i>							
15	Is the organization subject to the section 4960 tax on payment(s) of more than \$1,000,000 in remuneration or	4-	v					
	excess parachute payment(s) during the year?	15	X					
40	If "Yes," see the instructions and file Form 4720, Schedule N.		v					
16	Is the organization an educational institution subject to the section 4968 excise tax on net investment income?	16	X					
4-	If "Yes," complete Form 4720, Schedule O.							
17	Section 501(c)(21) organizations. Did the trust, or any disqualified or other person engage in any activities	4-						
	that would result in the imposition of an excise tax under section 4951, 4952 or 4953?	17						
	If "Yes," complete Form 6069.	<b>F</b>						
232005	12-13-22	Form	<b>990</b> (2022)					

6

232005 12-13-22

2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

Form	990 (2022) SOCIETY, INC. 39-1796		Р	age 6
Par	t VI Governance, Management, and Disclosure. For each "Yes" response to lines 2 through 7b below, and for a	"No" ı	respon	se
	to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes on Schedule O. See instructions.			
	Check if Schedule O contains a response or note to any line in this Part VI			X
Sec	tion A. Governing Body and Management			-
			Yes	No
1a	Enter the number of voting members of the governing body at the end of the tax year 1a15			
	If there are material differences in voting rights among members of the governing body, or if the governing			
	body delegated broad authority to an executive committee or similar committee, explain on Schedule O.			
b	Enter the number of voting members included on line 1a, above, who are independent 1b 15			
2	Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other	]		
	officer, director, trustee, or key employee?	2		X
3	Did the organization delegate control over management duties customarily performed by or under the direct supervision			
	of officers, directors, trustees, or key employees to a management company or other person?	3		X
4	Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?	4		X
5	Did the organization become aware during the year of a significant diversion of the organization's assets?	5		Х
6	Did the organization have members or stockholders?	6	Х	
7a	Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or			
	more members of the governing body?	7a	Х	
b	Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or			
	persons other than the governing body?	7b		x
8	Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:			
а	The governing body?	8a	Х	
b	Each committee with authority to act on behalf of the governing body?	8b	Х	
9	Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the			
	organization's mailing address? If "Yes," provide the names and addresses on Schedule O	9		X
Sec	tion B. Policies (This Section B requests information about policies not required by the Internal Revenue Code.)			
			Yes	No
10a	Did the organization have local chapters, branches, or affiliates?	10a		X
b	If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates,			
	and branches to ensure their operations are consistent with the organization's exempt purposes?	10b		
11a	Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?	11a	Х	
b	Describe on Schedule O the process, if any, used by the organization to review this Form 990.			
12a	Did the organization have a written conflict of interest policy? If "No," go to line 13	12a	Х	
b	Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?	12b	Х	
с	Did the organization regularly and consistently monitor and enforce compliance with the policy? If "Yes," describe			
	on Schedule O how this was done	12c	Х	
13	Did the organization have a written whistleblower policy?	13	Х	
14	Did the organization have a written document retention and destruction policy?	14	Х	
15	Did the process for determining compensation of the following persons include a review and approval by independent			
	persons, comparability data, and contemporaneous substantiation of the deliberation and decision?			
а	The organization's CEO, Executive Director, or top management official	15a	Х	
b	Other officers or key employees of the organization	15b		X
	If "Yes" to line 15a or 15b, describe the process on Schedule O. See instructions.			
16a	Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a			
	taxable entity during the year?	16a		X
b	If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation			
	in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's			
	exempt status with respect to such arrangements?	16b		
Sec	tion C. Disclosure			
17	List the states with which a copy of this Form 990 is required to be filed			
18	Section 6104 requires an organization to make its Forms 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)-	s only)	availal	ole
	for public inspection. Indicate how you made these available. Check all that apply.			
	Own website Another's website X Upon request Other (explain on Schedule O)			
19	Describe on Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and	d finan	cial	
	statements available to the public during the tax year.			
20	State the name, address, and telephone number of the person who possesses the organization's books and records			
	JULIA ARATA-FRATTA - 608-442-1908			
	2921 LANDMARK PLACE STE 300, MADISON, WI 53713			

7

232006 12-13-22

2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

Form **990** (2022)

HEMOSTASI	٢S	AND	THROMBOSIS	RESEARCH
SOCIETY.	II	NC.		

Form 990 (		SOCIETY					39-1
Part VII	Compensation	of Officers,	Directors,	Trustees,	Key Employees,	Highest	Compensated
	Employees an	d Independe	ent Contra	ctors			

### Employees, and independent Contractors

Check if Schedule O contains a response or note to any line in this Part VII

Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

1a Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization's tax year.
 List all of the organization's current officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation.
 Enter -0- in columns (D), (E), and (F) if no compensation was paid.

• List all of the organization's current key employees, if any. See the instructions for definition of "key employee."

• List the organization's five **current** highest compensated employees (other than an officer, director, trustee, or key employee) who received reportable compensation (box 5 of Form W-2, box 6 of Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than \$100,000 from the organization and any related organizations.

• List all of the organization's **former** officers, key employees, and highest compensated employees who received more than \$100,000 of reportable compensation from the organization and any related organizations.

• List all of the organization's **former directors or trustees** that received, in the capacity as a former director or trustee of the organization, more than \$10,000 of reportable compensation from the organization and any related organizations.

See the instructions for the order in which to list the persons above.

Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.

Name and thie         Average hours per weak four set of all accounts below         Description to the organization from the gradies below below         Description to the organization from related organization         Reportable compensation from related organization         Estimated sources and the organization           11         LORILYN JACOBERN-TEWS         40.00         X         X         110,445.         0.         15,967.           13         LORILYN JACOBERN-TEWS         40.00         X         X         0.         0.         0.           14         DESCRET (1) LORILYN JACOBERN-TEWS         40.00         X         X         0.         0.         0.           15         JBANNON CARFERTER, MD, MS         3.00         X         X         0.         0.         0.           16         JBANNON CARFERTER, MD, MS         3.00         X         X         0.         0.         0.           17         A REBECCA KRUSE JARRES, MD, MEA         3.00         X         X         0.         0.         0.           16         JUNNON MEES, MD, MAC, PACP, PAIA         3.00         X         X         0.         0.         0.           17         A RONFT FRAD, MD, FACP, PAIA         3.00         X         X         0.         0.         0.	(A)	(B)	(C)					(D)	(E)	(F)	
House per veek (list any nours for dig generation schema and and schema and hours for dig generation and schema and the schema and and the schema and the schema and the schema and the schema and the schema a	Name and title	Average	(do					one	Reportable	Reportable	Estimated
Week (ist ary burs for inelated organizations below inelwited)         Week (ist ary burs for inelated organizations below inelwited)         Inorit is is is is is is is is is is is is is		hours per	box	, unles	ss per	rson i	s both	n an	compensation	compensation	
(1)         LORILYN JACOBSEN-TEWS         40.00         x         110,445.         0.         15,967.           C12)         STARNON CARPERTER, MD, MS         3.00         x         x         0.         0.         0.           C3)         REBECCA KRUSE-JARRES, MD, MPH         3.00         x         x         0.         0.         0.           C4)         STANDON CARPERTRY (THEU JUNE)         x         x         0.         0.         0.           C4)         SHANDON MEEKS, MD, MBA         3.00         x         x         0.         0.         0.           C5)         JODAN SHAVT, MD, PHD         3.00         x         x         0.         0.         0.           VICE PRESIDENT         MALEC, MD, MSC         3.00         x         x         0.         0.         0.           VICE PRESIDENT PRESIDENT RELECT         X         X         0.         0.         0.         0.           C1)         JODAN SHAVT, MD, MSC         3.00         X         X         0.         0.         0.           TREASURER         X         X         0.         0.         0.         0.         0.           EBECARCH & AWARDS OFTICER         X         X <td></td> <td></td> <td></td> <td></td> <td></td> <td>recio</td> <td>i/irus</td> <td>lee)</td> <td></td> <td></td> <td></td>						recio	i/irus	lee)			
(1)         LORILYN JACOBSEN-TEWS         40.00         x         110,445.         0.         15,967.           C12)         STARNON CARPERTER, ND, MS         3.00         x         x         0.         0.         0.           C3)         REBECCA KRUSE-JARRES, ND, MP         3.00         x         x         0.         0.         0.           C4)         SHANDON CARPERTRY (THRU JUNE)         x         x         0.         0.         0.           C4)         SHANDON MEEKS, MD, MBA         3.00         x         x         0.         0.         0.           C5)         JORDAN SHAVIT, MD, PHD         3.00         x         x         0.         0.         0.           VICE PRESIDENT         MALEC, MD, MSC         3.00         x         x         0.         0.         0.           VICE PRESIDENT PRESIDENT RELECT         X         X         0.         0.         0.         0.           C1) <jordan md,="" msc<="" shavit,="" td="">         3.00         X         X         0.         0.         0.           VICE PRESIDENT MALEC, MD, MSC         3.00         X         X         0.         0.         0.           SECERTARY (THRU JUNE)         X         X         0</jordan>			irecto							J.	
(1)         LORILYN JACOBSEN-TEWS         40.00         x         110,445.         0.         15,967.           C12)         STARNON CARPERTER, ND, MS         3.00         x         x         0.         0.         0.           C3)         REBECCA KRUSE-JARRES, ND, MP         3.00         x         x         0.         0.         0.           C4)         SHANDON CARPERTRY (THRU JUNE)         x         x         0.         0.         0.           C4)         SHANDON MEEKS, MD, MBA         3.00         x         x         0.         0.         0.           C5)         JORDAN SHAVIT, MD, PHD         3.00         x         x         0.         0.         0.           VICE PRESIDENT         MALEC, MD, MSC         3.00         x         x         0.         0.         0.           VICE PRESIDENT PRESIDENT RELECT         X         X         0.         0.         0.         0.           C1) <jordan md,="" msc<="" shavit,="" td="">         3.00         X         X         0.         0.         0.           VICE PRESIDENT MALEC, MD, MSC         3.00         X         X         0.         0.         0.           SECERTARY (THRU JUNE)         X         X         0</jordan>			e or d	tee			sated		, , , , , , , , , , , , , , , , , , ,	•	
(1)         LORILYN JACOBSEN-TEWS         40.00         x         110,445.         0.         15,967.           C12)         STARNON CARPERTER, MD, MS         3.00         x         x         0.         0.         0.           C3)         REBECCA KRUSE-JARRES, MD, MPH         3.00         x         x         0.         0.         0.           C4)         STANDON CARPERTRY (THEU JUNE)         x         x         0.         0.         0.           C4)         SHANDON MEEKS, MD, MBA         3.00         x         x         0.         0.         0.           C5)         JODAN SHAVT, MD, PHD         3.00         x         x         0.         0.         0.           VICE PRESIDENT         MALEC, MD, MSC         3.00         x         x         0.         0.         0.           VICE PRESIDENT PRESIDENT RELECT         X         X         0.         0.         0.         0.           C1)         JODAN SHAVT, MD, MSC         3.00         X         X         0.         0.         0.           TREASURER         X         X         0.         0.         0.         0.         0.           EBECARCH & AWARDS OFTICER         X         X <td></td> <td></td> <td>rustee</td> <td>l trus</td> <td></td> <td>ee</td> <td>npen</td> <td></td> <td></td> <td>1099-NEC)</td> <td>•</td>			rustee	l trus		ee	npen			1099-NEC)	•
(1)         LORILYN JACOBSEN-TEWS         40.00         x         110,445.         0.         15,967.           C12)         STARNON CARPERTER, MD, MS         3.00         x         x         0.         0.         0.           C3)         REBECCA KRUSE-JARRES, MD, MPH         3.00         x         x         0.         0.         0.           C4)         STANDON CARPERTRY (THEU JUNE)         x         x         0.         0.         0.           C4)         SHANDON MEEKS, MD, MBA         3.00         x         x         0.         0.         0.           C5)         JODAN SHAVT, MD, PHD         3.00         x         x         0.         0.         0.           VICE PRESIDENT         MALEC, MD, MSC         3.00         x         x         0.         0.         0.           VICE PRESIDENT PRESIDENT RELECT         X         X         0.         0.         0.         0.           C1)         JODAN SHAVT, MD, MSC         3.00         X         X         0.         0.         0.           TREASURER         X         X         0.         0.         0.         0.         0.           EBECARCH & AWARDS OFTICER         X         X <td></td> <td></td> <td>dual t</td> <td>utiona</td> <td>_</td> <td>nploy</td> <td>st cor</td> <td>ar a</td> <td>1000 (120)</td> <td></td> <td></td>			dual t	utiona	_	nploy	st cor	ar a	1000 (120)		
(1)         LORLLY JACOBSEN-TEWS         40.00         x         110,445.         0.         15,967.           EXECUTIVE DIRECTOR         X         X         0.         0.         0.         0.           IMMEDIATE PAST PRESIDENT (BEGAN JUNE         X         X         0.         0.         0.           (3)         REBECCA KRUSE JARRES, MD, MPH         3.00         X         X         0.         0.         0.           (4)         SHANNON CAPEPARTER, ND, MPH         3.00         X         X         0.         0.         0.           (5)         JORDAN SRAVIT, MD, PHD         3.00         X         X         0.         0.         0.           (6)         LYNN MALEC, MD, MSC         3.00         X         X         0.         0.         0.           (7)         A. KONETI EAO, MD, FACP, FAHA         3.00         X         X         0.         0.         0.           (1)         JORDAN SRAVIT, MD, MSC         3.00         X         X         0.         0.         0.           (6)         JANE MARAJENIN, MD, MSC         3.00         X         X         0.         0.         0.           BUCATION OFFICER         X         X <td< td=""><td></td><td></td><td>Individ</td><td>In stitu</td><td>Office</td><td>Key er</td><td>Highe</td><td>Forme</td><td></td><td></td><td>o gamzanono</td></td<>			Individ	In stitu	Office	Key er	Highe	Forme			o gamzanono
(2) SHANNON CARPENTER, MD, MS       3.00       X       X       X       0.       0.       0.         IMMEDIATE PAST PRESIDENT (BEGAN JUNE       X       X       X       0.       0.       0.       0.         (3) REBECAR KURS-JARRES, MD, MHA       3.00       X       X       0.       0.       0.       0.         (4) SHANNON MERKS, MD, MBA       3.00       X       X       0.       0.       0.         (5) JORDAN SHAVIT, MD, PHD       3.00       X       X       0.       0.       0.         (6) LYN MALEC, MD, MSC       3.00       X       X       0.       0.       0.         (7) A. KORET FRAO, MD, FACP, FAHA       3.00       X       X       0.       0.       0.         SECRETARY (HRU JUNE)       X       X       0.       0.       0.       0.       0.         (9) BRYCE KERLIN, MD       3.00       X       X       0.       0.       0.       0.         (10) GOWTHAMI AREPALLY, MD       1.50       X       0.       0.       0.       0.         (11) WOLFGANG EERGMEIER, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0. <td< td=""><td>(1) LORILYN JACOBSEN-TEWS</td><td>40.00</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	(1) LORILYN JACOBSEN-TEWS	40.00									
IMMEDIATE PAST PRESIDENT (BEGAN JUNE         X         X         X         0.         0.         0.           (3) REBECCA RUNGE-JARRES, MD, MPH         3.00         X         X         0.         0.         0.         0.           IMMEDIATE PAST PRESIDENT (THRU JUNE)         X         X         0.         0.         0.         0.           (4) SHANNON MEEKS, MD, MEA         3.00         X         X         0.         0.         0.           (5) JORDAN SHAVIT, MD, PHD         3.00         X         X         0.         0.         0.           (6) LYNN MALEC, MD, MSC         3.00         X         X         0.         0.         0.           (7) A. KONSTI RAO, MD, PACP, FAHA         3.00         X         X         0.         0.         0.           SECRETARY (THRU JUNE)         X         X         0.         0.         0.         0.           BEUCATION OFFICER         X         X         0.         0.         0.         0.         0.           (10) GOWTHAMI AREPALLY, MD         3.000         X         X         0.         0.         0.           IBECATON         X         X         0.         0.         0.         0.	EXECUTIVE DIRECTOR		1		х				110,445.	Ο.	15,967.
(3)     REBECA KRUSE-JARRES, MD, MPH     3.00     X     X     0.     0.       IMMEDIATE PAST PRESIDENT (HRU JUNE)     X     X     0.     0.     0.       PRESIDENT     X     X     0.     0.     0.       (1)     SHANDN MEEKS, MD, MBA     3.00     X     X     0.     0.       (1)     JORDAN SHAVIT, MD, PHD     3.00     X     X     0.     0.       VICE PRESIDENT/FRESIDENT ELECT     X     X     0.     0.     0.       (1)     INMALEC, MD, MSC     3.00     X     X     0.     0.       (2)     AKONETI RAO, MD, FACP, FAHA     3.00     X     X     0.     0.       (3)     ARASH MAHAJERIN, MD, MSC     3.00     X     X     0.     0.       (3)     ARASH MAHAJERIN, MD, MSCR     3.00     X     X     0.     0.       (10)     GOWTHANI AREPALLY, MD     1.50     X     0.     0.     0.       DIRECTOR     X     X     0.     0.     0.     0.       (11)     MDLFGAM     1.50     X     0.     0.     0.       DIRECTOR     X     0.     0.     0.     0.     0.       (12)     DEBORAH SIEGAL, MD, MSC,	(2) SHANNON CARPENTER, MD, MS	3.00									
IMMEDIATE PAST PRESIDENT (THRU JUNE)         X         X         X         0.         0.         0.           (4) SHANNON MEERS, MD, MBA         3.000         X         X         0.         0.         0.           PRESIDENT         X         X         X         0.         0.         0.           VICE FRESIDENT/FRESIDENT ELECT         X         X         0.         0.         0.           (6) LYNN MALEC, MD, MSC         3.000         X         X         0.         0.         0.           (7) A. KONETI RAO, MD, FACP, FAHA         3.000         X         X         0.         0.         0.           (8) ARASH MAHAJERIN, MD, MSCR         3.000         X         X         0.         0.         0.           (9) BRYCE KERLIN, MD         3.000         X         X         0.         0.         0.           (10) GOWTHAMI AREPALLY, MD         1.500         X         0.         0.         0.         0.           DIRECTOR         X         0.         0.         0.         0.         0.         0.           DIRECTOR         X         0.         0.         0.         0.         0.         0.           DIRECTOR         X <td>IMMEDIATE PAST PRESIDENT (BEGAN JUNE</td> <td></td> <td>Х</td> <td></td> <td>Х</td> <td></td> <td></td> <td></td> <td>0.</td> <td>0.</td> <td>0.</td>	IMMEDIATE PAST PRESIDENT (BEGAN JUNE		Х		Х				0.	0.	0.
(4) SHANNON MEEKS, MD, MBA       3.00       X       X       X       0.       0.       0.         (5) JORDAN SHAVIT, MD, PHD       3.00       X       X       0.       0.       0.       0.         (5) JORDAN SHAVIT, MD, PHD       3.00       X       X       0.       0.       0.       0.         (5) JORDAN SHAVIT, MD, PHD       3.00       X       X       0.       0.       0.       0.         (6) LYNN MALEC, MD, MSC       3.00       X       X       0.       0.       0.       0.         (7) A. KORETI RAO, MD, FACP, FAHA       3.00       X       X       0.       0.       0.         (8) ARASH MAHAJERIN, MD, MSCR       3.00       X       X       0.       0.       0.         (9) BRYCE KERLIN, MD       3.00       X       X       0.       0.       0.         (10) GOWTHAMI AREPALLY, MD       1.50       X       0.       0.       0.       0.         (11) WOLFGANG BERGMEIER, PHD       1.50       X       0.       0.       0.       0.         (12) DEBORAH SIEGAL, MD, MSC, FRCPC       1.50       X       0.       0.       0.       0.         (13) BRIAN BRANCHFORD, MD       1.50	(3) REBECCA KRUSE-JARRES, MD, MPH	3.00									
PRESIDENT         X         X         X         X         0.         0.         0.           (5) JORDAN SHAVIT, MD, PHD         3.00         X         X         0.         0.         0.           VICE PRESIDENT FLECT         X         X         0.         0.         0.         0.           (6) LYNN MALEC, MD, MSC         3.00         X         X         0.         0.         0.           TREASURER         X         X         0.         0.         0.         0.           SECRETARY (HRU JUNE)         X         X         0.         0.         0.         0.           (8) ARSH MAHAJERIN, MD, MSCR         3.00         X         X         0.         0.         0.           (9) BRYCE KERLIN, MD         3.00         X         X         0.         0.         0.           VILO GOWTHAMI AREPALLY, MD         1.50         X         0.         0.         0.         0.           DIRECTOR         X         X         0.         0.         0.         0.         0.           (11) WOLFGANG BERGMEIER, PHD         1.50         DIRECTOR         X         0.         0.         0.           UIRECTOR         X <t< td=""><td>IMMEDIATE PAST PRESIDENT (THRU JUNE)</td><td></td><td>Х</td><td></td><td>Х</td><td></td><td></td><td></td><td>0.</td><td>0.</td><td>0.</td></t<>	IMMEDIATE PAST PRESIDENT (THRU JUNE)		Х		Х				0.	0.	0.
(5) JORDAN SHAVIT, MD, PHD       3.00       X       X       0.       0.       0.         VICE PRESIDENT/PRESIDENT ELECT       X       X       0.       0.       0.       0.         (6) LYNN MALEC, MD, MSC       3.00       X       X       0.       0.       0.       0.         TREASURER       X       X       0.       0.       0.       0.       0.         SECRETARY (THRU JUNE)       X       X       0.       0.       0.       0.       0.         SECRETARY (THU JUNE)       X       X       0.       0.       0.       0.       0.         BUCATION OFFICER       X       X       0. <t< td=""><td>(4) SHANNON MEEKS, MD, MBA</td><td>3.00</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	(4) SHANNON MEEKS, MD, MBA	3.00									
VICE PRESIDENT/PRESIDENT ELECT         X         X         X         0.         0.         0.           (6) LYNN MALEC, MD, MSC         3.00         X         X         X         0.         0.         0.           (7) A. KONETI RAO, MD, FACP, FAHA         3.00         X         X         0.         0.         0.           (7) A. KONETI RAO, MD, FACP, FAHA         3.00         X         X         0.         0.         0.           (8) ARASH MAHAJERIN, MD, MSCR         3.00         X         X         0.         0.         0.           (9) BYCE KERLIN, MD         3.00         X         X         0.         0.         0.           PRESEARCH & AWARDS OFFICER         X         X         0.         0.         0.         0.           DIRECTOR         X         X         0.         0.         0.         0.         0.           (11) GOWTHAMI AREPALLY, MD         1.50         X         0.         0.         0.         0.           DIRECTOR         X         0.         0.         0.         0.         0.         0.           (12) DEBORAH SIEGAL, MD, MSC, FRCPC         1.50         X         0.         0.         0.         0.	PRESIDENT		Х		Х				0.	0.	0.
(6)       LYNN MALEC, MD, MSC       3.00       X       X       X       0.       0.       0.         TREASURER       X       X       X       0.       0.       0.       0.         (7)       A. KONETI RAO, MD, FACP, FAHA       3.00       X       X       0.       0.       0.         SECRETARY (THRU JUNE)       X       X       0.       0.       0.       0.         (8)       ARASH MAHAJERIN, MD, MSCR       3.00       X       X       0.       0.       0.         (9)       BRYCE KERLIN, MD       3.00       X       X       0.       0.       0.         (10)       GOWTHANI AREPALLY, MD       1.50       X       0.       0.       0.         DIRECTOR       X       X       0.       0.       0.       0.         (11)       WOLFGANG BERGMEIER, PHD       1.50       X       0.       0.       0.         DIRECTOR       X       X       0.       0.       0.       0.       0.         (12)       DEGRAH SIEGAL, MD, MSC, FRCPC       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.	(5) JORDAN SHAVIT, MD, PHD	3.00									
TREASURER         X         X         X         X         0.         0.         0.           (7) A. KONETI RAO, MD, FACP, FAHA SECRETARY (THRU JUNE)         3.00         X         X         X         0.         0.         0.           (8) ARASH MAHAJERIN, MD, MSCR         3.00         X         X         0.         0.         0.           EDUCATION OFFICER         X         X         0.         0.         0.         0.           (9) ERYCE KERLIN, MD         3.00         X         X         0.         0.         0.           (10) GOWTHANI AREPALLY, MD         1.50         X         X         0.         0.         0.           (11) WOLFGANG BERGMEIER, PHD         1.50         X         0.         0.         0.         0.           (12) DEBORAH SIEGAL, MD, MSC, FRCPC         1.50         X         0.         0.         0.         0.           DIRECTOR         X         0.         0.         0.         0.         0.         0.           (12) DEBORAH SIEGAL, MD, MSC, FRCPC         1.50         X         0.         0.         0.         0.           DIRECTOR         X         0.         0.         0.         0.         0.	VICE PRESIDENT/PRESIDENT ELECT		Х		Х				0.	0.	0.
(7) A. KONETI RAO, MD, FACP, FAHA       3.00       X       X       X       0.       0.       0.         SECRETARY (THRU JUNE)       X       X       X       0.       0.       0.       0.         (8) ARASH MAHAJERIN, MD, MSCR       3.00       X       X       0.       0.       0.       0.         EDUCATION OFFICER       X       X       0.       0.       0.       0.       0.         (9) BRYCE KERLIN, MD       3.00       X       X       0.       0.       0.       0.         (10) GOWTHAMI AREPALLY, MD       1.50       X       X       0.       0.       0.         DIRECTOR       X       X       0.       0.       0.       0.       0.         (11) WOLFGANG BEEGMEIER, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.       0.         (14) MARY CUSHMAN, MD, MSC <td>(6) LYNN MALEC, MD, MSC</td> <td>3.00</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	(6) LYNN MALEC, MD, MSC	3.00									
SECRETARY (THRU JUNE)XXX00.0.(8) ARASH MAHAJERIN, MD, MSCR3.00XXX0.0.0.BDUCATION OFFICERXXX0.0.0.0.(9) BRYCE KERLIN, MD3.00XXX0.0.0.RESEARCH & AWARDS OFFICERXXX0.0.0.0.(10) GOWTHAMI AREPALLY, MD1.50X0.0.0.0.DIRECTORXX0.0.0.0.0.(11) WOLFGANG BERGMEIER, PHD1.50X0.0.0.0.DIRECTORX0.0.0.0.0.0.(12) DEBORAH SIEGAL, MD, MSC, FRCPC1.50X0.0.0.0.DIRECTORX0.0.0.0.0.0.(13) BRIAN BRANCHFORD, MD1.50X0.0.0.0.DIRECTORX0.0.0.0.0.0.(14) MARY CUSHMAN, MD, MSC1.50X0.0.0.0.DIRECTORX0.0.0.0.0.0.(15) ALAN MAST, MD, PHD1.50X0.0.0.0.DIRECTORX0.0.0.0.0.0.(16) ALISA WOLBERG, PHD1.50X0.0.0.0.DIRECTORX0.0.0.0.0.<	TREASURER		Х		Х				0.	0.	0.
(8) ARASH MAHAJERIN, MD, MSCR       3.00       X       X       X       0.       0.       0.         (9) BRYCE KERLIN, MD       3.00       X       X       X       0.       0.       0.         (9) BRYCE KERLIN, MD       3.00       X       X       X       0.       0.       0.         (10) GOWTHAMI AREPALLY, MD       1.50       X       X       0.       0.       0.         DIRECTOR       X       X       0.       0.       0.       0.       0.         (11) WOLFGANG BERGMEIER, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       X       0.       0.       0.       0.       0.         (12) DEBORAH SIEGAL, MD, MSC, FRCPC       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.	(7) A. KONETI RAO, MD, FACP, FAHA	3.00									
EDUCATION OFFICER         X         X         X         0.	SECRETARY (THRU JUNE)		Х		Х				0.	0.	0.
(9)       BRYCE KERLIN, MD       3.00       X       X       X       0.       0.       0.         (10)       GOWTHAMI AREPALLY, MD       1.50       X       X       0.       0.       0.       0.         (11)       WOLFGANG BERGMEIER, PHD       1.50       X       X       0.       0.       0.       0.         (11)       WOLFGANG BERGMEIER, PHD       1.50       X       0.       0.       0.       0.         (12)       DEBORAH SIEGAL, MD, MSC, FRCPC       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.       0.         (12)       DEBORAH SIEGAL, MD, MSC, FRCPC       1.50       X       0.       0.       0.       0.       0.         DIRECTOR       X       0.		3.00									
RESEARCH & AWARDS OFFICER         X         X         X         0.         0.         0.         0.           (10) GOWTHAMI AREPALLY, MD         1.50         X         0. <td< td=""><td>EDUCATION OFFICER</td><td></td><td>Х</td><td></td><td>Х</td><td></td><td></td><td></td><td>0.</td><td>0.</td><td>0.</td></td<>	EDUCATION OFFICER		Х		Х				0.	0.	0.
(10) GOWTHAMI AREPALLY, MD       1.50       X       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.         (11) WOLFGANG BERGMEIER, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (12) DEBORAH SIEGAL, MD, MSC, FRCPC       1.50       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (13) BRIAN BRANCHFORD, MD       1.50       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (14) MARY CUSHMAN, MD, MSC       1.50       0.       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.       0.         (15) ALAN MAST, MD, PHD       1.50       0.       0.       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.	(9) BRYCE KERLIN, MD	3.00									
DIRECTOR         X         0. <t< td=""><td></td><td></td><td>Х</td><td></td><td>Х</td><td></td><td></td><td></td><td>0.</td><td>0.</td><td>0.</td></t<>			Х		Х				0.	0.	0.
(11) WOLFGANG BERGMEIER, PHD       1.50       X       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.         (12) DEBORAH SIEGAL, MD, MSC, FRCPC       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (13) BRIAN BRANCHFORD, MD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (14) MARY CUSHMAN, MD, MSC       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (15) ALAN MAST, MD, PHD       1.50       X       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.       0.         (16) ALISA WOLBERG, PHD       1.50       X       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.	(10) GOWTHAMI AREPALLY, MD	1.50									
DIRECTOR         X         0. <t< td=""><td></td><td></td><td>Х</td><td></td><td></td><td></td><td></td><td></td><td>0.</td><td>0.</td><td>0.</td></t<>			Х						0.	0.	0.
(12) DEBORAH SIEGAL, MD, MSC, FRCPC       1.50       X       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.         (13) BRIAN BRANCHFORD, MD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (14) MARY CUSHMAN, MD, MSC       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (15) ALAN MAST, MD, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (16) ALISA WOLBERG, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (17) MING LIM, MBBCHIR, MSCR       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.	(11) WOLFGANG BERGMEIER, PHD	1.50									
DIRECTOR         X         0. <t< td=""><td></td><td></td><td>Х</td><td></td><td></td><td></td><td></td><td></td><td>0.</td><td>0.</td><td>0.</td></t<>			Х						0.	0.	0.
(13) BRIAN BRANCHFORD, MD       1.50       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.         (14) MARY CUSHMAN, MD, MSC       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (15) ALAN MAST, MD, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (16) ALISA WOLBERG, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.	(12) DEBORAH SIEGAL, MD, MSC, FRCPC	1.50									
DIRECTOR       X       0.       0.       0.       0.         (14) MARY CUSHMAN, MD, MSC       1.50       X       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.         (15) ALAN MAST, MD, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (16) ALISA WOLBERG, PHD       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.         (17) MING LIM, MBBCHIR, MSCR       1.50       X       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.			Х						0.	0.	0.
(14) MARY CUSHMAN, MD, MSC       1.50       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.         (15) ALAN MAST, MD, PHD       1.50       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.         (16) ALISA WOLBERG, PHD       1.50       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.		1.50									-
DIRECTOR         X         0. <t< td=""><td></td><td></td><td>Х</td><td></td><td></td><td></td><td></td><td></td><td>0.</td><td>0.</td><td>0.</td></t<>			Х						0.	0.	0.
(15) ALAN MAST, MD, PHD       1.50       0.0.0.0.         DIRECTOR       X       0.0.0.0.         (16) ALISA WOLBERG, PHD       1.50       0.0.0.0.         DIRECTOR       X       0.0.0.0.         (17) MING LIM, MBBCHIR, MSCR       1.50       0.0.0.0.         DIRECTOR       X       0.0.0.0.	(14) MARY CUSHMAN, MD, MSC	1.50									_
DIRECTOR         X         0.         0.         0.           (16) ALISA WOLBERG, PHD         1.50         .         .         .         .           DIRECTOR         X         0.         0.         0.         0.         0.           (17) MING LIM, MBBCHIR, MSCR         1.50         X         0.         0.         0.         0.           DIRECTOR         X         0.         0.         0.         0.         0.			Х						0.	0.	0.
(16) ALISA WOLBERG, PHD       1.50       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.         (17) MING LIM, MBBCHIR, MSCR       1.50       X       0.       0.       0.       0.         DIRECTOR       X       0.       0.       0.       0.       0.       0.	(15) ALAN MAST, MD, PHD	1.50									_
DIRECTOR         X         0. <t< td=""><td></td><td></td><td>Х</td><td></td><td></td><td></td><td></td><td></td><td>0.</td><td>0.</td><td>0.</td></t<>			Х						0.	0.	0.
(17) MING LIM, MBBCHIR, MSCR 1.50 X 0. 0. 0.		1.50									
DIRECTOR X 0. 0. 0.			Х						0.	0.	0.
		1.50									
	DIRECTOR		Х						0.	0.	

8

232007 12-13-22

Form **990** (2022)

HEMOSTASI		THF	ROM	IBC	SI	S	RI	ESEARCH	20 15	0.00		_	0
Form 990 (2022) SOCIETY,							+ 0		39-17	900	0/2	Ра	ige <b>8</b>
(A)	tees, Key Emp (B)		ees,			ynes	at C	Ompensated Employee (D)	, ,			(E)	
(A) Name and title	Average		<b>(C)</b> Position			ı		(D) Reportable	(E) Reportable			(F) imate	ч
Name and the	hours per			check more than one ess person is both an				compensation	compensatio	n		ount o	
	week					or/trus		from	from related			other	
	(list any	ector						the	organizations		comp		
	hours for related	or dir	e			ated		organization	(W-2/1099-MIS	C/		m the	
	organizations	ustee	truste		e	bens		(W-2/1099-MISC/ 1099-NEC)	1099-NEC)		•	nizatio relate	
	below	lual tr	tional	Ι.	) ploye	st con yee	-	1099-NEC)				nizatio	
	line)	Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former				orgu	nzane	,110
(18) AYESHA ZIA, MD, MSCR	1.50	_	-		Ť		_						
DIRECTOR		х						0.		0.			Ο.
								110.115		_			
1b Subtotal								110,445.		0.	15	,96	
c Total from continuation sheets to Part VI								0.		0.	1 0	0.0	0.
d Total (add lines 1b and 1c)								110,445.		0.	10	,96	)/•
2 Total number of individuals (including but n	ot limited to th	ose	liste	ed at	oove	e) wh	o re	eceived more than \$100,	000 of reportable				1
compensation from the organization												Yes	⊥ No
• Did the exercited list and former officer							la : a			ſ		165	NU
<b>3</b> Did the organization list any <b>former</b> officer,			-	-	-				•		~		х
<ul><li>line 1a? If "Yes," complete Schedule J for st</li><li>For any individual listed on line 1a, is the su</li></ul>	uch individual				+:	d		ar componention from t		····	3		<u></u>
-	-		-						-		4		х
<ul><li>and related organizations greater than \$150</li><li>5 Did any person listed on line 1a receive or a</li></ul>										····	4		
rendered to the organization? If "Yes." com											5		Х
Section B. Independent Contractors	piele Scriedule	eji	or si	JCH ,	oers	:011 .					5		
1 Complete this table for your five highest cor	mpensated inc	lene	ende	nt co	ontr	actor	rs tl	nat received more than \$	100 000 of comp	ensat	ion froi	n	
the organization. Report compensation for t	-									onout			
(A)			<u>orre</u> in	. <u>g</u>				(B)			(C)		
Name and business	address							Description of s	ervices	С	ompen		ı
VERSITI WISCONSIN, INC.								PROFESSIONAL					
PO BOX 2178, MILWAUKEE, W	I 53201							EMPLOYER ORG	ANIZATIO		250	, 22	25.
·													
2 Total number of independent contractors (ir	ncluding but n	ot lir	nited	d to	thos	se lis	ted	above) who received mo	ore than				
\$100,000 of compensation from the organiz	•				1	1							
											-	~ ~	

232008 12-13-22

			SOCIETY, INC.				39-1796	672 Page <b>9</b>
Pa	rt V	/111						_
			Check if Schedule O contains a response of	or note to any lin	e in this Part VIII (A)	(B)	(C)	<u> </u>
					Total revenue	Related or exempt	Unrelated	Revenue excluded
						function revenue	business revenue	from tax under sections 512 - 514
6 6	-	_	Federated campaigns 1a					30010113 312 314
Contributions, Gifts, Grants and Other Similar Amounts	'							
ũg			Membership dues   1b     Fundraising events   1c					
fts,		d Related organizations						
nila			Government grants (contributions)					
Sin			All other contributions, gifts, grants, and					
her		•		307,516.				
oti		a	Noncash contributions included in lines 1a-1f	,				
Con		-	Total. Add lines 1a-1f		1,307,516.			
<u> </u>				Business Code				
ø	2	а	PROGRAM REVENUE	541900	313,479.	313,479.		
, vic	_		DUES	900099	313,479. 111,185.	111,185.		
Ser		С				,		
		d						
Program Service Revenue		е						
Pro		f	All other program service revenue					
			Total. Add lines 2a-2f		424,664.			
	3		Investment income (including dividends, intere					
			other similar amounts)		39,198.			39,198.
	4		Income from investment of tax-exempt bond p					
	5		Royalties					
			(i) Real	(ii) Personal				
	6	а	Gross rents 6a					
		b	Less: rental expenses 6b					
		С	Rental income or (loss) 6c					
		d	Net rental income or (loss)					
	7	а	Gross amount from sales of (i) Securities	(ii) Other				
			assets other than inventory <b>7a</b>					
		b	Less: cost or other basis					
anu			and sales expenses 7b					
evenue		С	Gain or (loss) 7c					
ñ			Net gain or (loss)	1				
Other	8	а	Gross income from fundraising events (not					
õ			including \$ of					
			contributions reported on line 1c). See					
		_	Part IV, line 18					
			Less: direct expenses 8b					
	~		Net income or (loss) from fundraising events					
	9	а	Gross income from gaming activities. See					
		Ŀ	Part IV, line 19 9a Less: direct expenses 9b					
			• • • • • • • • • • • • • • • • • • • •					
	40		Net income or (loss) from gaming activities					
	10	а	Gross sales of inventory, less returns and allowances <b>10a</b>					
		h	and allowances <u>10a</u> Less: cost of goods sold <u>10b</u>	1				
			Net income or (loss) from sales of inventory					
		U	The mean of the second of the	Business Code				
sn	11	а						
neo		a b						
ella ver		c						
Miscellaneous Revenue			All other revenue					
Σ			Total. Add lines 11a-11d					
	12		Total revenue. See instructions		1,771,378.	424,664.	0.	39,198.
23200					•	•	•	Form <b>990</b> (2022)

232009 12-13-22

# 16000905 788028 13399.1AS01

10

39-1796672 Page 10

SOCIETY, INC. Form 990 (2022)

ecti	ion 501(c)(3) and 501(c)(4) organizations must compl			plete column (A).	
	Check if Schedule O contains a respons			(0)	
	not include amounts reported on lines 6b, 8b, 9b, and 10b of Part VIII.	<b>(A)</b> Total expenses	<b>(B)</b> Program service expenses	<b>(C)</b> Management and general expenses	<b>(D)</b> Fundraising expenses
1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21	926,057.	926,057.		
2	Grants and other assistance to domestic individuals. See Part IV, line 22	20,000.	20,000.		
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16				
4	Benefits paid to or for members				
5	Compensation of current officers, directors,				
	trustees, and key employees	126,412.	7,400.	119,012.	
6	Compensation not included above to disqualified				
	persons (as defined under section $4958(f)(1)$ ) and				
,	persons described in section 4958(c)(3)(B)	88,773.	76,234.	12,421.	118
7	Other salaries and wages	00,775.	10,234.	14,441.	TTO
3	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)	5,892.	4,038.	1,854. 4,465.	
9	Other employee benefits	14,193.	9,728.	4,465.	
)	Payroll taxes	14,955.	10,250.	4,705.	
l a	Fees for services (nonemployees):				
a b	Management				
		90,420.		90,420.	
C L	Accounting	50,420.		50,420.	
d	Lobbying				
e 4	Professional fundraising services. See Part IV, line 17 Investment management fees	8,544.		8,544.	
f	Other. (If line 11g amount exceeds 10% of line 25,	0,511.		0,544.	
g	column (A), amount, list line 11g expenses on Sch 0.)	154,060.	76,060.	78,000.	
2	Advertising and promotion	1,084.	1,084.	, , , , , , , , , , , , , , , , , , , ,	
2 3	Office expenses	13,681.	9,928.	3,753.	
5 4	Information technology	8,410.	575201	8,410.	
		0,410.		0,410.	
5 6	Royalties				
, 7		5,679.	5,511.	168.	
, 3	Travel Payments of travel or entertainment expenses	5,0,5.	5,511.	1001	
, ,	for any federal, state, or local public officials				
9	Conferences, conventions, and meetings	225,237.	212,405.	12,832.	
, )	Interest	3,241.	861.	2,380.	
, 1	Payments to affiliates	~,211.			
2	Depreciation, depletion, and amortization				
-	Insurance	15,046.	6,315.	8,722.	9
ł	Other expenses. Itemize expenses not covered above. (List miscellaneous expenses on line 24e. If line 24e amount exceeds 10% of line 25, column (A), amount, list line 24e expenses on Schedule 0.)				
а	RETURN OF UNEXPENDED FU	59,174.	59,174.		
b	JOURNAL SUBSCRIPTIONS	31,144.	15,420.	15,724.	
с ч					
d		2 606		2 606	
	All other expenses	2,606. 1,814,608.	1,440,465.	2,606. 374,016.	127
5	Total functional expenses. Add lines 1 through 24e	I,0I4,000.	, <u>40</u> 0,400.	5/4,010.	<u>_</u>
5	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined				
	educational campaign and fundraising solicitation.				

232010 12-13-22

Check here

if following SOP 98-2 (ASC 958-720)

Form 990 (2022)

HEMOSTASI	S AND	THROMBOSIS	RESEARCH
SOCIETY,	INC.		

	990 (2 <b>t X</b>	SOCIETY, INC.		39-	1796672 Page 11
	L X	Check if Schedule O contains a response or note to any line in this Part X			
			(A)	<u> </u>	(B)
			Beginning of year		End of year
	1	Cash - non-interest-bearing	236,251.	1	285,884
	2	Savings and temporary cash investments	2,462,036.	2	2,024,711.
	3	Pledges and grants receivable, net	265,275.	3	766,408
	4	Accounts receivable, net	7,020.	4	0,
	5	Loans and other receivables from any current or former officer, director,	.,	-	-
	Ŭ	trustee, key employee, creator or founder, substantial contributor, or 35%			
		controlled entity or family member of any of these persons		5	
	6	Loans and other receivables from other disqualified persons (as defined			
	•	under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)		6	
	7	Notes and loans receivable, net		7	
Assets	8	Inventories for sale or use		8	
As	9	Prepaid expenses and deferred charges	95,049.	9	108,870
		Land, buildings, and equipment: cost or other			,
		basis. Complete Part VI of Schedule D 10a			
	b	Less: accumulated depreciation10b		10c	
	11	Investments - publicly traded securities	1,100,929.	11	944,308
	12	Investments - other securities. See Part IV, line 11	8,757.	12	9,733
	13	Investments - program-related. See Part IV, line 11		13	
	14	Intangible assets		14	
	15	Other assets. See Part IV, line 11		15	
	16	Total assets. Add lines 1 through 15 (must equal line 33)	4,175,317.	16	4,139,914
	17	Accounts payable and accrued expenses	104,271.	17	60,644
	18	Grants payable		18	
	19	Deferred revenue	117,702.	19	336,830
	20	Tax-exempt bond liabilities	,	20	-
	21	Escrow or custodial account liability. Complete Part IV of Schedule D	4,020.	21	8,163
6	22	Loans and other payables to any current or former officer, director,	- · ·		
Liabilities		trustee, key employee, creator or founder, substantial contributor, or 35%			
lige		controlled entity or family member of any of these persons		22	
<del>۳</del>	23	Secured mortgages and notes payable to unrelated third parties		23	
	24	Unsecured notes and loans payable to unrelated third parties		24	
	25	Other liabilities (including federal income tax, payables to related third			
		parties, and other liabilities not included on lines 17-24). Complete Part X			
		of Schedule D		25	
	26	Total liabilities. Add lines 17 through 25	225,993.	26	405,637
		Organizations that follow FASB ASC 958, check here			
Ses		and complete lines 27, 28, 32, and 33.			
an	27	Net assets without donor restrictions	2,151,656.	27	1,800,777
Ba	28	Net assets with donor restrictions	1,797,668.	28	1,933,500
pd I		Organizations that do not follow FASB ASC 958, check here			
щ,		and complete lines 29 through 33.			
S S	29	Capital stock or trust principal, or current funds		29	
set	30	Paid-in or capital surplus, or land, building, or equipment fund		30	
As	31	Retained earnings, endowment, accumulated income, or other funds		31	
Net Assets or Fund Balances	32	Total net assets or fund balances	3,949,324.	32	3,734,277
-	33	Total liabilities and net assets/fund balances	4,175,317.	33	4,139,914 Form <b>990</b> (202)

232011 12-13-22

HEMOSTASIS AND THROMBOSIS RESEAR	HEMOSTASIS	AND	THROMBOSIS	RESEARC
----------------------------------	------------	-----	------------	---------

Form	990 (2022) SOCIETY, INC.	39-179	6672	Pag	<sub>ge</sub> 12
Pa	rt XI Reconciliation of Net Assets				
	Check if Schedule O contains a response or note to any line in this Part XI		<u></u>		
1	Total revenue (must equal Part VIII, column (A), line 12)	1	1,771		
2	Total expenses (must equal Part IX, column (A), line 25)	2	1,814		
3	Revenue less expenses. Subtract line 2 from line 1	3			30.
4	Net assets or fund balances at beginning of year (must equal Part X, line 32, column (A))	4	3,949		
5	Net unrealized gains (losses) on investments	5	-171	.,8:	17.
6	Donated services and use of facilities	6			
7	Investment expenses	7			
8	Prior period adjustments	8			
9	Other changes in net assets or fund balances (explain on Schedule O)	9			0.
10	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 32,				
	column (B))	10	<u>3,734</u>	l,2'	77.
Pa	rt XII Financial Statements and Reporting				
	Check if Schedule O contains a response or note to any line in this Part XII				
				Yes	No
1	Accounting method used to prepare the Form 990: Cash X Accrual Other				
	If the organization changed its method of accounting from a prior year or checked "Other," explain on Schedule	О.			
2a	Were the organization's financial statements compiled or reviewed by an independent accountant?		2a		X
	If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed	on a			
	separate basis, consolidated basis, or both:				
	Separate basis Consolidated basis Both consolidated and separate basis				
b	Were the organization's financial statements audited by an independent accountant?		2b	Х	
	If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate	basis,			
	consolidated basis, or both:				
	X Separate basis Consolidated basis Both consolidated and separate basis				
с	If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the	e audit,			
	review, or compilation of its financial statements and selection of an independent accountant?		2c	Х	
	If the organization changed either its oversight process or selection process during the tax year, explain on Sch	edule O.			
3a	As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the				
	Uniform Guidance, 2 C.F.R. Part 200, Subpart F?		3a		X
b	If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required				
	or audits, explain why on Schedule O and describe any steps taken to undergo such audits		3b		

Form 990 (2022)

232012 12-13-22

SCHEDULE A (Form 990)			Co	OMB No. 1545-0047								
Department of the Treasury Internal Revenue Service				Attach to Form 990 or Form 990-EZ. Go to www.irs.gov/Form990 for instructions and the latest information.						Open to Public Inspection		
SOCI				STASIS AND ETY, INC.	THROMBOSIS F	RESEAF	RCH		3	identification number $9-1796672$		
Par	tI	Reason	or Public (	Charity Status.	(All organizations must c	omplete th	nis part.) S	ee instructior	IS.			
The o 1 [ 2 [ 3 [ 4 [	rgani	<ul> <li>ganization is not a private foundation because it is: (For lines 1 through 12, check only one box.)</li> <li>A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).</li> <li>A school described in section 170(b)(1)(A)(ii). (Attach Schedule E (Form 990).)</li> <li>A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).</li> <li>A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:</li> </ul>										
5 [		An organizatio	on operated fo	or the benefit of a col	llege or university owned	or operate	ed by a go	overnmental u	nit describe	ed in		
6 [ 7 [	X	<ul> <li>An organization operated for the benefit of a college or university owned or operated by a governmental unit described in section 170(b)(1)(A)(iv). (Complete Part II.)</li> <li>A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).</li> <li>An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(v).</li> </ul>										
8 [					(1)(A)(vi). (Complete Part	,						
9 [		-	-	-	in section 170(b)(1)(A)(i ulture (see instructions).		-		-	-		
10 [		An organization activities related income and u	ed to its exen nrelated busir	npt functions, subjec	than 33 1/3% of its supp t to certain exceptions; a (less section 511 tax) fro	and (2) no	more than	33 1/3% of it	s support f	rom gross investment		
11					vely to test for public saf	etv. See	section 50	)9(a)(4).				
12 [ a		more publicly lines 12a thro ] <b>Type I.</b> A su	supported or ugh 12d that upporting orga	ganizations describe describes the type o anization operated, s	vely for the benefit of, to d in <b>section 509(a)(1)</b> o f supporting organization upervised, or controlled l gularly appoint or elect a	r <b>section</b> and composite supply its supply	509(a)(2). plete lines ported org	See <b>section</b> 12e, 12f, and anization(s), t	<b>509(a)(3).</b> ( l 12g. ypically by	Check the box on		
			-	complete Part IV, Se		, ,						
b		٦ Ŭ		•	or controlled in connect	ion with its	s supporte	ed organizatio	n(s), by hav	ring		
		control or m	nanagement o	f the supporting orga	anization vested in the sa	ame perso	ns that co	ntrol or mana	ge the supp	ported		
		organization	n(s). <b>You mus</b>	t complete Part IV,	Sections A and C.							
с		] Type III fun	ctionally inte	grated. A supporting	g organization operated i	in connect	ion with, a	and functiona	lly integrate	d with,		
			-		). You must complete F							
d			-	• •	oorting organization operation				•			
			,	0 0	ation generally must sati	,			an attentiv	veness		
			-		nplete Part IV, Sections							
е			•		written determination from			турет, туре	п, туре п			
f	Ento	r the number of			nally integrated supportir							
				about the supporte								
		i) Name of suppo		(ii) EIN	(iii) Type of organization	(iv) Is the orga in your governi	inization listed ng document?	(v) Amount o	f monetary	(vi) Amount of other		
		organization			(described on lines 1-10 above (see instructions))	Yes	No	support (see ii	nstructions)	support (see instructions)		
Total												

# HEMOSTASIS AND THROMBOSIS RESEARCH SOCIETY, INC.

39-1796672 Page 2

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization

fails to qualify under the tests listed below, please complete Part III.)

Schedule A (Form 990) 2022

Part II

Sec	ction A. Public Support						
Cale	ndar year (or fiscal year beginning in)	(a) 2018	<b>(b)</b> 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1	Gifts, grants, contributions, and						
	membership fees received. (Do not						
	include any "unusual grants.")	1227448.	4175999.	1303461.	1404188.	1307516.	9418612.
2	Tax revenues levied for the organ-						
	ization's benefit and either paid to						
	or expended on its behalf						
3	The value of services or facilities						
	furnished by a governmental unit to						
	the organization without charge						
4	Total. Add lines 1 through 3	1227448.	4175999.	1303461.	1404188.	1307516.	9418612.
5	The portion of total contributions						
-	by each person (other than a						
	governmental unit or publicly						
	supported organization) included						
	on line 1 that exceeds 2% of the						
	amount shown on line 11,						
	column (f)						4889140.
6	Public support. Subtract line 5 from line 4.						4529472.
	ction B. Total Support						19291720
	ndar year (or fiscal year beginning in)	(a) 2018	<b>(b)</b> 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
	Amounts from line 4	1227448.	4175999.	1303461.	1404188.	1307516.	9418612.
8	Gross income from interest,		11,0000	10001010			71200220
U	dividends, payments received on						
	securities loans, rents, royalties,						
	and income from similar sources	25,430.	60,794.	11,609.	33,262.	39,198.	170,293.
•		25,450.	00,7940	11,005.	55,202.	55,150.	110,255
9	Net income from unrelated business						
	activities, whether or not the						
	business is regularly carried on						
10	Other income. Do not include gain						
	or loss from the sale of capital						
	assets (Explain in Part VI.)						9588905.
	Total support. Add lines 7 through 10		````			10 1	,656,449.
12	Gross receipts from related activities,	•	,				,050,449.
13	First 5 years. If the Form 990 is for th						
800	organization, check this box and stor ction C. Computation of Publi	o here					
							47.24 %
	Public support percentage for 2022 (I					14	1 = 0.0
	Public support percentage from 2021					15	
16a	33 1/3% support test - 2022. If the other						V
	stop here. The organization qualifies		-				
b	<b>33 1/3% support test - 2021.</b> If the open states have The experimentian states						
4-	and <b>stop here.</b> The organization qual		• •				
17a	10% -facts-and-circumstances test						
	and if the organization meets the fact			-	-	-	
	meets the facts-and-circumstances te	6	•		•		
b	10% -facts-and-circumstances test	-					10% or
	more, and if the organization meets th						
40	organization meets the facts-and-circl				••••		
18	Private foundation. If the organization	on did not check a	box on line 13, 16a	a, 16b, 17a, or 17b	o, check this box a		
						Schedule A	(Form 990) 2022

39-1796672 Page 3

Schedule A			SOCIETY,			
Part III	Support	Schedule for	<sup>•</sup> Organizatior	ns Describ	oed in Section 509(a)(2)	

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support						
Calendar year (or fiscal year beginning in)	(a) 2018	<b>(b)</b> 2019	(c) 2020	(d) 2021	(e) 2022	2 (f) Total
1 Gifts, grants, contributions, and						
membership fees received. (Do not						
include any "unusual grants.")						
2 Gross receipts from admissions, merchandise sold or services per- formed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
<b>3</b> Gross receipts from activities that are not an unrelated trade or bus-						
iness under section 513					_	
4 Tax revenues levied for the organ- ization's benefit and either paid to or expended on its behalf						
5 The value of services or facilities						
furnished by a governmental unit to						
the organization without charge						
6 Total. Add lines 1 through 5						
<b>7a</b> Amounts included on lines 1, 2, and 3 received from disqualified persons						
<b>b</b> Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of \$5,000 or 1% of the amount on line 13 for the year						
<b>c</b> Add lines 7a and 7b						
8 Public support. (Subtract line 7c from line 6.)						
Section B. Total Support			-			
Calendar year (or fiscal year beginning in)	(a) 2018	<b>(b)</b> 2019	(c) 2020	(d) 2021	(e) 2022	2 (f) Total
9 Amounts from line 6						
<b>10a</b> Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources						
<ul> <li>b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975</li> </ul>						
<ul> <li>c Add lines 10a and 10b</li> <li>11 Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on</li> </ul>						
12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)						
<b>13</b> Total support. (Add lines 9, 10c, 11, and 12.)						
<b>14</b> First 5 years. If the Form 990 is for t	ne organization's fi	rst, second, third,	fourth, or fifth tax	year as a section	501(c)(3) orgai	nization,
Section C. Computation of Publ		-			<u> </u>	
<b>15</b> Public support percentage for 2022 (			column (f))		15	%
16 Public support percentage from 202					16	%
Section D. Computation of Inves					<u> </u>	
<ul><li>17 Investment income percentage for 2</li><li>18 Investment income percentage from</li></ul>		B	line 13, column (f))		17 18	<u>%</u> %
19a 33 1/3% support tests - 2022. If the						
more than 33 1/3%, check this box a						
<b>b 33 1/3% support tests - 2021.</b> If the	-	-	· ·			'3%, and
line 18 is not more than 33 1/3%, che	-					
20 Private foundation. If the organization						
232023 12-09-22		,	. ,			dule A (Form 990) 2022
		16	5			. ,

2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

### HEMOSTASIS AND THROMBOSIS RESEARCH SOCIETY, INC.

Schedule A (Form 990) 2022

# Part IV | Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, Part I, complete Sections A and B. If you checked box 12b, Part I, complete Sections A and C. If you checked box 12c, Part I, complete Sections A, D, and E. If you checked box 12d, Part I, complete Sections A and D, and complete Part V.)

# Section A. All Supporting Organizations

- 1 Are all of the organization's supported organizations listed by name in the organization's governing documents? If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.
- 2 Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).
- 3a Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.
- b Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.
- c Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.
- 4a Was any supported organization not organized in the United States ("foreign supported organization")? // "Yes," and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.
- b Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If "Yes," describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.
- c Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If "Yes," explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.
- **5a** Did the organization add, substitute, or remove any supported organizations during the tax year? If "Yes." answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).
- b Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?
- c Substitutions only. Was the substitution the result of an event beyond the organization's control?
- Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? If "Yes." provide detail in Part VI.
- 7 Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (as defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If "Yes," complete Part I of Schedule L (Form 990).
- 8 Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? If "Yes." complete Part I of Schedule L (Form 990).
- 9a Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If "Yes," provide detail in Part VI.
- b Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If "Yes," provide detail in Part VI.
- c Did a disgualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If "Yes," provide detail in Part VI.
- 10a Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If "Yes," answer line 10b below.
- b Did the organization have any excess business holdings in the tax year? (Use Schedule C. Form 4720, to determine whether the organization had excess business holdings.)

17

232024 12-09-22

10b Schedule A (Form 990) 2022

39-1796672 Page 4

1

2

3a

3b

3c

4a

4b

4c

5a

5b

5c

6

7

8

9a

9b

9c

10a

Yes No

Sche	edule A (Form 990) 2022 SOCIETY, INC.	39-179667	2 Pa	age <b>5</b>
	rt IV Supporting Organizations (continued)			0
			Yes	No
11	Has the organization accepted a gift or contribution from any of the following persons?			
а	A person who directly or indirectly controls, either alone or together with persons described on lines 11b and			
	11c below, the governing body of a supported organization?	11a		
b	A family member of a person described on line 11a above?	11b		
	A 35% controlled entity of a person described on line 11a or 11b above? If "Yes" to line 11a, 11b, or 11c, provide			
	detail in Part VI.	11c		
Sec	ction B. Type I Supporting Organizations			
			Yes	No
1	Did the governing body, members of the governing body, officers acting in their official capacity, or membership of more supported organizations have the power to regularly appoint or elect at least a majority of the organization's or directors, or trustees at all times during the tax year? <i>If</i> " <i>No</i> ," <i>describe in</i> <b>Part VI</b> <i>how the supported organization(s, effectively operated, supervised, or controlled the organization's activities. If the organization had more than one supportation, describe how the powers to appoint and/or remove officers, directors, or trustees were allocated amore than one support to the powers to appoint and/or remove officers, directors, or trustees were allocated amore than one support to the powers to appoint and/or remove officers, directors, or trustees were allocated amore than the powers to appoint and/or remove officers, directors, or trustees were allocated amore than the powers to appoint and/or remove officers, directors, or trustees were allocated amore than the powers to appoint and/or remove officers, directors, or trustees were allocated amore than the powers to appoint and/or remove officers, directors, or trustees were allocated amore than the powers to appoint and/or remove officers, directors, or trustees were allocated amore than the powers to appoint and/or remove officers, directors, or trustees were allocated amore than the power to be appoint and the powers of the powers to appoint and the power to appoint and the power to the power to appoint and the power to the power to be appoint and to be appoint and to be appoint a</i>	officers, ) pported ng the		
-	supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.	1		
2	Did the organization operate for the benefit of any supported organization other than the supported			
	organization(s) that operated, supervised, or controlled the supporting organization? If "Yes," explain in			
	Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated,			
800	supervised, or controlled the supporting organization.	2		
000				
			Yes	No
1	Were a majority of the organization's directors or trustees during the tax year also a majority of the directors			
	or trustees of each of the organization's supported organization(s)? If "No," describe in Part VI how control			
	or management of the supporting organization was vested in the same persons that controlled or managed			
800	the supported organization(s). ction D. All Type III Supporting Organizations	1		
Sec				
			Yes	No
1	Did the organization provide to each of its supported organizations, by the last day of the fifth month of the			
	organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax			
	year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the			
	organization's governing documents in effect on the date of notification, to the extent not previously provided?	1		
2	Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported			
	organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how			
	the organization maintained a close and continuous working relationship with the supported organization(s).	2		
3	By reason of the relationship described on line 2, above, did the organization's supported organizations have a			
	significant voice in the organization's investment policies and in directing the use of the organization's			
	income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization's			

#### supported organizations played in this regard. Section E. Type III Functionally Integrated Supporting Organizations

1 Check the box next to the method that the organization used to satisfy the	e Integral Part Test during the year (see instructions).
--	--

- a The organization satisfied the Activities Test. Complete line 2 below.
- **b** \_\_\_\_ The organization is the parent of each of its supported organizations. *Complete* line 3 *below.*

С		The organization supported a governmental entity.	Describe in Part VI how you supported a governmental entity (see instruction	n <u>s).</u>
---	--	---	--	--------------

18

- 2 Activities Test. Answer lines 2a and 2b below.
- a Did substantially all of the organization's activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.
- b Did the activities described on line 2a, above, constitute activities that, but for the organization's involvement, one or more of the organization's supported organization(s) would have been engaged in? *If* "Yes," *explain in* Part VI *the reasons for the organization's position that its supported organization(s) would have engaged in these activities but for the organization's involvement.*
- **3** Parent of Supported Organizations. **Answer lines 3a and 3b below.**

a Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations? *If* "Yes" or "No" provide details in **Part VI.** 

**b** Did the organization exercise a substantial degree of direction over the policies, programs, and activities of each of its supported organizations? *If* "Yes," *describe in* **Part VI** *the role played by the organization in this regard.* 

Yes No

3

232025 12-09-22

16000905 788028 13399.1AS01

2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

	HEMOSTASIS AND THROMBOSI	S RI	ESEARCH					
Sche	edule A (Form 990) 2022 SOCIETY, INC.			39-1796672 Page 6				
Pa	rt V Type III Non-Functionally Integrated 509(a)(3) Supporting	Orga	nizations					
1	Check here if the organization satisfied the Integral Part Test as a qualifying	trust or	n Nov. 20, 1970 ( <i>explain ii</i>	Part VI). See instructions.				
	All other Type III non-functionally integrated supporting organizations must c	omplet	e Sections A through E.	-				
Sect	Section A - Adjusted Net Income (A) Prior Year (B) Current Year (optional)							
1	Net short-term capital gain	1						
2	Recoveries of prior-year distributions	2						
3	Other gross income (see instructions)	3						
4	Add lines 1 through 3.	4						
5	Depreciation and depletion	5						
6	Portion of operating expenses paid or incurred for production or							
	collection of gross income or for management, conservation, or							
	maintenance of property held for production of income (see instructions)	6						
7	Other expenses (see instructions)	7						
8	Adjusted Net Income (subtract lines 5, 6, and 7 from line 4)	8						
Sect	ion B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)				
1	Aggregate fair market value of all non-exempt-use assets (see							
	instructions for short tax year or assets held for part of year):							
a	Average monthly value of securities	1a						
b	Average monthly cash balances	1b						
C	Fair market value of other non-exempt-use assets	1c						
d	Total (add lines 1a, 1b, and 1c)	1d						
е	Discount claimed for blockage or other factors							
	(explain in detail in Part VI):							
_2	Acquisition indebtedness applicable to non-exempt-use assets	2						
_3	Subtract line 2 from line 1d.	3						
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount,							
	see instructions).	4						
_5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5						
6	Multiply line 5 by 0.035.	6						
7	Recoveries of prior-year distributions	7						
8	Minimum Asset Amount (add line 7 to line 6)	8						
Sect	ion C - Distributable Amount			Current Year				
_1	Adjusted net income for prior year (from Section A, line 8, column A)	1						
2	Enter 0.85 of line 1.	2						
3	Minimum asset amount for prior year (from Section B, line 8, column A)	3						
4	Enter greater of line 2 or line 3.	4						
5	Income tax imposed in prior year	5						
6	Distributable Amount. Subtract line 5 from line 4, unless subject to							
	emergency temporary reduction (see instructions).	6						
7	Check here if the current year is the organization's first as a non-functionally	integra	ted Type III supporting org	ganization (see				

instructions).

Schedule A (Form 990) 2022

232026 12-09-22

Sche Par	dule A (Form 990) 2022 SOCIETY, INC. t V Type III Non-Functionally Integrated 509(	a)(3) Supporting Orga	nizations (continu		9-1796672 Page 7
	on D - Distributions		nizations (continu	iea)	Current Year
<u>3ecu</u> 1	Amounts paid to supported organizations to accomplish exer	matauraasas		1	Guirent rea
2	Amounts paid to supported organizations to accomplish exer Amounts paid to perform activity that directly furthers exemp			- 1	
2	organizations, in excess of income from activity	t purposes of supported		2	
3	Administrative expenses paid to accomplish exempt purpose	2	3		
4	Amounts paid to acquire exempt-use assets		,	4	
5	Qualified set-aside amounts (prior IRS approval required - pro	ovide details in <b>Part VI</b> )		5	
6	Other distributions ( <i>describe in</i> <b>Part VI</b> ). See instructions.			6	
7	<b>Total annual distributions.</b> Add lines 1 through 6.			7	
8	Distributions to attentive supported organizations to which the	e organization is responsive			
	(provide details in Part VI). See instructions.	0		8	
9	Distributable amount for 2022 from Section C, line 6			9	
10	Line 8 amount divided by line 9 amount			10	
Secti	on E - Distribution Allocations (see instructions)	(i) Excess Distributions	(ii) Underdistributior Pre-2022	IS	(iii) Distributable Amount for 2022
1	Distributable amount for 2022 from Section C, line 6				
2	Underdistributions, if any, for years prior to 2022 (reason-				
	able cause required - explain in Part VI). See instructions.				
3	Excess distributions carryover, if any, to 2022				
a	From 2017				
b	From 2018				
c	From 2019				
d	From 2020				
e	From 2021				
f	Total of lines 3a through 3e				
g	Applied to underdistributions of prior years				
h	Applied to 2022 distributable amount				
i	Carryover from 2017 not applied (see instructions)				
j	Remainder. Subtract lines 3g, 3h, and 3i from line 3f.				
4	Distributions for 2022 from Section D,				
	line 7: \$				
	Applied to underdistributions of prior years				
b	Applied to 2022 distributable amount				
C	Remainder. Subtract lines 4a and 4b from line 4.				
5	Remaining underdistributions for years prior to 2022, if				
	any. Subtract lines 3g and 4a from line 2. For result greater				
	than zero, explain in Part VI. See instructions.				
6	Remaining underdistributions for 2022. Subtract lines 3h				
	and 4b from line 1. For result greater than zero, explain in				
	Part VI. See instructions.				
7	Excess distributions carryover to 2023. Add lines 3j and 4c.				
8	Breakdown of line 7:				
а	Excess from 2018				
b	Excess from 2019				
с	Excess from 2020				
d	Excess from 2021				
e	Excess from 2022				
				-	

Schedule A (Form 990) 2022

232027 12-09-22

	(5	HEMOSTASIS AND SOCIETY, INC.	THROMBOSIS	RESEARCH	39-1796672 Page 8
Part VI	Part IV, Section A, lines 1, line 1; Part IV, Section D, I	<b>nation.</b> Provide the explan 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9	9b, 9c, 11a, 11b, and 1 i E, lines 1c, 2a, 2b, 3a	1c; Part IV, Section B, line , and 3b; Part V, line 1; Pa	or 17b; Part III, line 12; s 1 and 2; Part IV, Section C, rt V, Section B, line 1e; Part V,
232028 12-09-2	22				Schedule A (Form 990) 2022
/= 00 1			21		

# \*\* PUBLIC DISCLOSURE COPY

# Schedule of Contributors

Attach to Form 990 or Form 990-PF. Go to www.irs.gov/Form990 for the latest information. OMB No. 1545-0047

Employer identification number

39-1796672

Sc	hedule	В
<b>~</b>		

(Form 990)

Department of the Treasury Internal Revenue Service

Name	of the	organizatio	r
INALLE		organizatio	L

HEMOSTASIS AND THROMBOSIS RESEARCH INC.

SOCIETY, Organization type (check one):

Filers of:	Section:
Form 990 or 990-EZ	$\fbox$ 501(c)( 3 ) (enter number) organization
	4947(a)(1) nonexempt charitable trust <b>not</b> treated as a private foundation
	527 political organization
Form 990-PF	501(c)(3) exempt private foundation
	4947(a)(1) nonexempt charitable trust treated as a private foundation
	501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.

Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

# General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling \$5,000 or more (in money or property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

# Special Rules

X For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33 1/3% support test of the regulations under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of (1) \$5,000; or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h; or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, total contributions of more than \$1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I (entering "N/A" in column (b) instead of the contributor name and address), II, and III.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, contributions exclusively for religious, charitable, etc., purposes, but no such contributions totaled more than \$1,000. If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Don't complete any of the parts unless the General Rule applies to this organization because it received nonexclusively religious, charitable, etc., contributions totaling \$5,000 or more during the year \_\_\_\_\_\_\$

Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990), but it must answer "No" on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ or on its Form 990-PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990).

LHA For Paperwork Reduction Act Notice, see the instructions for Form 990, 990-EZ, or 990-PF.



SOCIE:	TY, INC.	39	-1796672
Part I	Contributors (see instructions). Use duplicate copies of Part I if additiona	Il space is needed.	
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
1		\$ <u>325,500.</u>	Person X Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
2		\$330,000.	Person X Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
3		\$190,600.	Person     X       Payroll
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
4		\$ <u>100,500.</u>	Person X Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
5		\$168,785.	Person X Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
6_		\$128,000.	Person X Payroll Noncash (Complete Part II for noncash contributions.)

Schedule B (Form 990) (2022)

223452 11-15-22

24 2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

# Schedule B (Form 990) (2022) Name of organization

HEMOSTASIS AND THROMBOSIS RESEARCH

Page 2
Employer identification number

39-1796670

Part I	<b>Contributors</b> (see instructions). Use duplicate copies of Part I if	additional space is needed.	
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
7		\$40,500.	Person X Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		\$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		\$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		\$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		\$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		\$	Person Payroll Noncash (Complete Part II for noncash contributions.)

223452 11-15-22

25 2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

SOCIETY, INC.

HEMOSTASIS AND THROMBOSIS RESEARCH

Page 2 Employer identification number

39-1796672

	3 (Form 990) (2022)		Page <b>3</b>
			Employer identification number
	FASIS AND THROMBOSIS RESEARCH FY, INC.		39-1796672
Part II	Noncash Property (see instructions). Use duplicate copies of Par	t II if additional space is needed	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate (See instructions)	
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate (See instructions.)	
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate (See instructions.	
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate (See instructions.)	
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate (See instructions)	
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate (See instructions.	
		\$	

223453 11-15-22

Schedule B (Form 990) (2022)

# 16000905 788028 13399.1AS01

26 2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

Schedule	B (Form 990) (2022)		Page 4
			Employer identification number
	TASIS AND THROMBOSIS RE TY, INC.	SEARCH	39-1796672
Part III	Exclusively religious, charitable, etc., contribut from any one contributor. Complete columns (a	) through (e) and the following line en	section 501(c)(7), (8), or (10) that total more than \$1,000 for the year ntry. For organizations
	completing Part III, enter the total of exclusively religious, Use duplicate copies of Part III if additional	space is needed.	riess for the year. (Enter this into, once.)
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
		(e) Transfer of git	
	Transferee's name, address, a		Relationship of transferor to transferee
(a) No. from	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
Part I			
	Transferee's name, address, a	(e) Transfer of gi	ift Relationship of transferor to transferee
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
		(e) Transfer of git	ift
	Transferee's name, address, a	nd ZIP + 4	Relationship of transferor to transferee
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
		(e) Transfer of git	ift
	Transferee's name, address, a	nd ZIP + 4	Relationship of transferor to transferee
223454 11-15	5-22		Schedule B (Form 990) (2022)

16000905 788028 13399.1AS01

27 2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

(Forn	HEDULE D 990)	Part IV, line 6, 7, 8, 9, 10,	nization answered "Ye	es" on Form 990,		OMB No. 1545-0047
-	Revenue Service	Go to www.irs.gov/Form990				Inspection
Nam	, et alle et gannaatien	HEMOSTASIS AND THRO	MBOSIS RESE	ARCH		r identification number
D		SOCIETY, INC.				39-1796672
Par		s Maintaining Donor Advised		Similar Funds or	Accounts.	Complete if the
	organization ans	wered "Yes" on Form 990, Part IV, line				
			(a) Donor advis	sed funds	(b) Funds a	nd other accounts
1		/ear				
2	Aggregate value of cont	ributions to (during year)				
3	Aggregate value of grant	ts from (during year)				
4	Aggregate value at end	of year				
5		orm all donors and donor advisors in v	vriting that the assets h	neld in donor advised f	unds	
	are the organization's pr	operty, subject to the organization's e	exclusive legal control?			Yes No
6		orm all grantees, donors, and donor a				
	•	and not for the benefit of the donor or	<b>v v</b>		2	
	• •	nefit?			0	Yes No
Par		Easements. Complete if the org				
1		on easements held by the organization			10, 110 1	
•		nd for public use (for example, recreat	· · · ·	Preservation of a h	istoriaally impo	stant land area
		1 ( 1 )		=	, ,	
	Protection of natu		L	Preservation of a c	ertified historic	structure
-	Preservation of op	•				
2		gh 2d if the organization held a qualif	ed conservation contri	bution in the form of a		
	day of the tax year.					l at the End of the Tax Year
а	Total number of conserv	ation easements			. 2a	
b	Total acreage restricted	by conservation easements			<b>2</b> b	
С	Number of conservation	easements on a certified historic stru	icture included in (a)		2c	
d	Number of conservation	easements included in (c) acquired a	fter July 25,2006, and	not on a		
	historic structure listed i	n the National Register			2d	
3		easements modified, transferred, rele				ig the tax
	year			, ,		•
4	-	property subject to conservation eas	ement is located			
5		ave a written policy regarding the peri		ction handling of		
•	•	ent of the conservation easements it	<b>U</b> , 1			Yes No
6		s devoted to monitoring, inspecting, I				
U	otali and volunteer nour		narialing of violations, a		ation casemen	to during the year
7	Amount of overances inc	urred in monitoring increating hand	ling of violations, and a	nforming concernation	aaaamanta du	ring the year
7	Amount of expenses inc	urred in monitoring, inspecting, hand	ling of violations, and e	enorcing conservation	easements du	ring the year
-						
8		easement reported on line 2(d) above				
		ii)?				Yes No
9	In Part XIII, describe how	v the organization reports conservation	on easements in its reve	enue and expense stat	ement and	
	balance sheet, and inclu	de, if applicable, the text of the footn	ote to the organization	's financial statements	that describes	s the
		g for conservation easements.				
Par		s Maintaining Collections of		easures, or Othe	r Similar As	sets.
	Complete if the o	rganization answered "Yes" on Form	990, Part IV, line 8.			
1a	If the organization elected	ed, as permitted under FASB ASC 958	8, not to report in its re	venue statement and b	balance sheet v	works
	of art, historical treasure	s, or other similar assets held for pub	lic exhibition, education	n, or research in furthe	erance of public	0
		(III the text of the footnote to its finan				
b		ed, as permitted under FASB ASC 958			nce sheet work	(s of
	-	or other similar assets held for public				
		ounts relating to these items:				61 1100,
		•			¢	
		n Form 990, Part VIII, line 1				
•	(ii) Assets included in F				······· * <u> </u>	
2		red or held works of art, historical trea			n, provide	
	-	equired to be reported under FASB A	-			
		rm 990, Part VIII, line 1				
	Assets included in Form					
LHA	For Paperwork Reduct	ion Act Notice, see the Instructions	for Form 990.		Sch	edule D (Form 990) 2022
232051	09-01-22					
			28			
009	05 788028 133	399.1AS01	2022.04020	HEMOSTASIS	AND THR	OMBOSIS 13399

16000905 788028 13399.1AS	1	6	0	0	09	0	5		- 5	78	3	8	0	2	8	3	1	.3	3:	3 !	9	9		1	Α	S	(	)
---------------------------	---	---	---	---	----	---	---	--	-----	----	---	---	---	---	---	---	---	----	----	-----	---	---	--	---	---	---	---	---

<sup>2022.04020</sup> HEMOSTASIS AND THROMBOSIS 13399.11

	HEMOSTA	SIS AND THE	ROMBOSIS R	ESEARCH				_	
	dule D (Form 990) 2022 SOCIETY		<u></u>			39-17			'age <b>2</b>
Par	t III Organizations Maintaining C	ollections of Ar	t, Historical Tre	easures, or Othe	er Simila	r Assets	contii	nued)	
3	Using the organization's acquisition, accessi	on, and other records	s, check any of the	following that make s	significant	use of its			
	collection items (check all that apply):								
а	Public exhibition	d	Loan or exc	hange program					
b	Scholarly research	е	Other						
с	Preservation for future generations								
4	Provide a description of the organization's co	ollections and explair	how they further th	ne organization's exe	mpt purpc	se in Part	XIII.		
5	During the year, did the organization solicit of	or receive donations o	of art, historical trea	sures, or other simila	r assets				
	to be sold to raise funds rather than to be ma	aintained as part of th	ne organization's co	llection?			Yes		No
Par	t IV Escrow and Custodial Arran	gements. Comple	ete if the organizatio	n answered "Yes" or	n Form 990	), Part IV, I	line 9, or		
	reported an amount on Form 990, Pa		-						
1a	Is the organization an agent, trustee, custod	ian or other intermedi	ary for contribution	s or other assets not	included				
	on Form 990, Part X?						Yes	X	No
b	If "Yes," explain the arrangement in Part XIII								
		•	0				Amoun	t	
с	Beginning balance				1c				
	Additions during the year								
е	Distributions during the year								
f	Ending balance								
	Did the organization include an amount on F					X	Yes		No
	If "Yes," explain the arrangement in Part XIII.				• • • • • • • • • • • • • • • • • • • •	······		X	_
Par									
		(a) Current year	(b) Prior year	(c) Two years back		years back	(e) Fou	r vears	back
1a	Beginning of year balance	225,229.	201,028.			,		,	
	Contributions	,	,	200,000.					
	Net investment earnings, gains, and losses	-38,553.	24,201.			1,028.			
	Grants or scholarships								
	Other expenditures for facilities								
e		10,000.							
÷	and programs Administrative expenses	9.							
		176,667.	225,229.	201,028.		1,028.			
g	End of year balance Provide the estimated percentage of the curr	· · · · · ·	,	,		-,			
2	Board designated or quasi-endowment	100	%	jj nelu as.					
a L	Permanent endowment • 0000	<u> </u>	70						
b	0000								
С		-							
0-	The percentages on lines 2a, 2b, and 2c sho	•			h -				
за	Are there endowment funds not in the posse	ession of the organiza	tion that are held ar	nd administered for t	ne			Yes	No
	organization by:						0-(1)	163	X
	(i) Unrelated organizations						3a(i)		X
	(ii) Related organizations						3a(ii)		
-	If "Yes" on line 3a(ii), are the related organiza						3b		<u> </u>
4 Dar	Describe in Part XIII the intended uses of the tVI Land, Buildings, and Equipm		wment funds.						
T ai			Part IV line 11a S	Coo Form 000 Part V	lino 10				
	Complete if the organization answere						(-1) 5	1	
	Description of property	(a) Cost or o			Accumulat		( <b>d)</b> Boo	k valu	ie
		basis (investr	Dasis	(other) de	epreciation				
-	Land								
b	Buildings								
	Leasehold improvements			<b> </b>					
	Equipment								
	Other								
Total	. Add lines 1a through 1e. (Column (d) must e	aual Form 990. Part J	X. column (B). line 1	0c.)					0.

Schedule D (Form 990) 2022

232052 09-01-22

HEMOSTASIS	AND	THROMBOSIS	RESEARCH
------------	-----	------------	----------

Schedule D (Form 990) 2022 SOCIETY, IN	С.	39-1796	5672 Page 3
Part VII Investments - Other Securities.			
Complete if the organization answered "Yes"			
(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year n	narket value
(1) Financial derivatives			
(2) Closely held equity interests			
(3) Other			
(A)			
(B)			
(C)			
(D)			
(E)			
(F)			
(G)			
(H)			
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 12.)			
Part VIII Investments - Program Related.			
Complete if the organization answered "Yes"	on Form 990, Part IV, line	11c. See Form 990, Part X, line 13.	
(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year n	narket value
(1)			
(2)			
(3)			
(4)			
(5)			
(6)			
(7)			
(8)			
(9)		-	
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 13.)		-	
Part IX Other Assets.			
Complete if the organization answered "Yes"	on Form 990. Part IV. line	11d. See Form 990. Part X. line 15.	
-	Description		Book value
(1)	2 000 i p ii 0 i i		
(2)			
(3)			
(4)			
(5)			
(6)			
(7)			
(8)			
(9)			
Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities.	e 15.)		
	on Form 000 Dart IV line	110 or 11f Soc Form 000, Dort V line 25	
Complete if the organization answered "Yes"	on Form 990, Part IV, line		Dealestalue
1. (a) Description of liability		(b)	Book value
(1) Federal income taxes			
(2)			
(3)			
(4)			
(5)			
(6)			
(7)			
(8)			
(9)			
Total. (Column (b) must equal Form 990, Part X, col. (B) line	05)		
<b>2.</b> Liability for uncertain tax positions. In Part XIII, provide			

organization's liability for uncertain tax positions under FASB ASC 740. Check here if the text of the footnote has been provided in Part XIII ....

232053 09-01-22

Schedule D (Form 990) 2022

	HEMOSTASIS AND THROMBOSIS R	ESEAR	CH			
Sche	dule D (Form 990) 2022 SOCIETY, INC.				1796672	Page <b>4</b>
Par	t XI Reconciliation of Revenue per Audited Financial Statemen	ts With	Revenue per Re	turn.		
	Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.					
1	Total revenue, gains, and other support per audited financial statements			1	1,591,	,017.
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:					
а	Net unrealized gains (losses) on investments	2a	-171,817.			
b	Donated services and use of facilities	2b				
с	Recoveries of prior year grants	2c				
d	Other (Describe in Part XIII.)	2d	-8,544.			
е	Add lines 2a through 2d			2e	-180,	
3	Subtract line 2e from line 1			3	1,771,	,378.
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:					
а	Investment expenses not included on Form 990, Part VIII, line 7b	4a				
b	Other (Describe in Part XIII.)	4b				
с	Add lines <b>4a</b> and <b>4b</b>			4c		0.
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I. line 12.)			5	1,771,	,378.
Pa	t XII Reconciliation of Expenses per Audited Financial Stateme	nts With	n Expenses per F	Return	า.	
	Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.					
1	Total expenses and losses per audited financial statements			1	1,806,	,064.
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:					
а	Donated services and use of facilities	2a				
b	Prior year adjustments	2b				
с	Other losses	2c				
d	Other (Describe in Part XIII.)	2d				
е	Add lines 2a through 2d			2e		0.
3	Subtract line 2e from line 1			3	1,806,	,064.
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:					
а	Investment expenses not included on Form 990, Part VIII, line 7b	4a	8,544.			
b	Other (Describe in Part XIII.)	4b				
с	Add lines 4a and 4b			4c		,544.
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.)			5	1,814,	,608.
Pa	t XIII Supplemental Information.					

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

# PART IV, LINE 2B:

HEMOSTASIS AND THROMBOSIS RESEARCH SOCIETY, INC. COLLECTS JOINT

MEMBERSHIPS ON BEHALF OF THEMSELVES AND FOUNDATION FOR WOMEN & GIRLS WITH

BLOOD DISORDERS.

PART V, LINE 4:

HTRS' ENDOWMENT CONSISTS OF FUNDS DESIGNATED BY THE BOARD OF DIRECTORS TO

31

FUNCTION AS A QUASI-ENDOWMENT. THE FUND HAS BEEN ESTABLISHED FOR THE

FURTHERANCE OF HTRS' MISSION AND FINANCIAL STABILITY.

# PART XI, LINE 2D - OTHER ADJUSTMENTS:

INVESTMENT MANAGEMENT FEES REPORTED ON FORM 990, PART IX,

232054 09-01-22

Schedule D (Form 990) 2022

16000905 788028 13399.1AS01

<u>.</u>	F (F 000) 0000			THROMBOSIS	39-1796672 Page 5
Part X	e D (Form 990) 2022 [III   Supplemental Inform	mation (continu	JINC •		
LINE	111.				-8,544.
					Schedule D (Form 990) 2022

SCHEDULE I		G	arants and Oth	er Assistan	ce to Organ	izations.			OMB No. 1545-0047
(Form 990)		Go	vernments, an ete if the organization	d Individual	s in the Ŭni <sup>-</sup>	ted States			2022
Department of the Treasury		·	Ū	Attach to Form					Open to Public
Internal Revenue Service				.gov/Form990 for	the latest information	ation.			Inspection
······································	HEMOSTASI SOCIETY,		OMBOSIS RES	EARCH				Employer	identification number 39-1796672
Part I General Inform	ation on Grants a	nd Assistance							
<ol> <li>Does the organization criteria used to award</li> <li>Describe in Part IV the</li> </ol>	the grants or assis	tance?				•			X Yes No
Part II Grants and Oth	er Assistance to I	Domestic Organiz	zations and Domestic be duplicated if addition	Governments. C	complete if the orga	anization answered "Y	′es" on Form 990, Parl	IV, line 21,	for any
<b>1 (a)</b> Name and address or governm		<b>(b)</b> EIN	<b>(c)</b> IRC section (if applicable)	(d) Amount of cash grant	<b>(e)</b> Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance		Purpose of grant or assistance
BOARD OF REGENTS OF T	HE UNIVERSITY								
OF WISCONSIN SYSTEM -	432 N LAKE		STATE OF						
ST - MADISON, WI 5370	6	37-1625460	WISCONSIN	59,800.	0.			RESEARCH	
UNIVERSITY OF NORTH C. CHAPEL HILL FOUNDATION AIRPORT DRIVE CB1270	N INC 104								
HILL, NC 27599		59-1711424	501(C)(3)	82,500.	0.			RESEARCH	
REGENTS OF THE UNIVER MICHIGAN - 19000 HUBB DEARBORN, MI 48126		38-6006309	501(C)(3)	165,000.	0.			RESEARCH	
CHILDREN'S HOSPITAL O FOUNDATION - 3011 W G #218 - DETROIT, MI 48	RAND BLVD,	32-0087353	501(C)(3)	9,294.	0.			RESEARCH	
BETH ISRAEL DEACONESS CENTER INC - 330 BROOD - BOSTON, MA 02215	MEDICAL	04-2103881		16,200.	0.			RESEARCH	
THE CHILDREN'S HOSPIT. PHILADELPHIA - 3401 C BLVD - PHILADELPHA, P.	IVIC CENTER	23-1352166	501(C)(3)	146,803.	0.			RESEARCH	
2 Enter total number of	section 501(c)(3) ar	nd government or	ganizations listed in the	e line 1 table				•	11.
3 Enter total number of				·····				<u></u>	0.

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) 2022

SOCIETY, INC. Schedule I (Form 990)

39-1796672 Page 1

(a) Name and address of organization or government	<b>(b)</b> EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
JOHNS HOPKINS UNIVERSITY							
3910 KESWICK RD NO N43278							
BALTIMORE, MD 21211-2226	52-0595110	501(C)(3)	64,800.	0.			RESEARCH
JNIVERSITY OF PITTSBURGH							
500 ROSS STREET 154-0455							
PITTSBURGH, PA 15262-0001	25-0965591	501(C)(3)	64,800.	0.			RESEARCH
JNIVERSITY OF VERMONT AND STATE							
AGRICULUTURAL COLLEGE - 590 MAIN							
STREET 311K - BURLINGTON, VT 05405	03-0179440	501(C)(3)	82,500.	0.			RESEARCH
RESEARCH INSTITUTE AT NATIONWIDE			, ,				
CHILDREN'S HOSPITAL - 700							
CHILDREN'S DRIVE - COLUMBUS, OH							
43205-2664	31-6056230	501(C)(3)	86,400.	0.			RESEARCH
EMORY UNIVERSITY							
201 DOWMAN DR							
ATLANTA, GA 30322	58-0566256	501(C)(3)	147,300.	0.			RESEARCH
,							

Schedule I (Form 990)

Schedule I (Form 990) 2022

SOCIETY, INC.

39-1796672

Page 2

Part III Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22. Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	<b>(c)</b> Amount of cash grant	(d) Amount of non- cash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance
TUDENT RESEARCH AWARDS	8	20,000.	0.		
Part IV Supplemental Information. Provide the information	equired in Part I, lir	l ne 2; Part III, column	(b); and any other ac	ditional information.	
ART I, LINE 2:					
ER EXECUTED GRANT AGREEMENTS, TH	E INVESTIO	ATOR AND R	ECIPIENT A	GREE TO	

PROVIDE HEMOSTASIS AND THROMBOSIS RESEARCH SOCIETY, INC. (HTRS) WITH

WRITTEN REPORTS IN FORM AND SUBSTANCE AND WITH DETAIL AND SUBSTANTIATION

THAT IS ACCEPTABLE TO HTRS ON OR BEFORE SPECIFIED DEADLINES. AWARD

PAYMENTS FROM HTRS TO THE RECIPIENT ARE CONTINGENT UPON 1) THE TIMELY

RECEIPT OF REPORTS AND 2) THE FORMAL ACKNOWLEDGMENT BY HTRS THAT ALL THE

OTHER REPORTING REQUIREMENTS HAVE BEEN MET.

SCHEDULE O (Form 990)

Department of the Treasury Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ Complete to provide information for responses to specific questions on Form 990 or 990-EZ or to provide any additional information.

Attach to Form 990 or Form 990-EZ.

Go to www.irs.gov/Form990 for the latest information.

Open to Public Inspection Employer identification number

39-1796672

OMB No. 1545-0047

HEMOSTASIS AND THROMBOSIS RESEARCH Name of the organization SOCIETY,

FORM 990, PART I, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:

INC.

MENTORING, WORKFORCE DEVELOPMENT, AND CONTINUING MEDICAL EDUCATION FOR

PHYSICIANS, INVESTIGATORS, AND ALLIED HEALTH PROFESSIONALS INTERESTED

IN ADVANCING CARE FOR PEOPLE WITH HEMOSTATIC AND THROMBOTIC DISORDERS.

LINE 1, DESCRIPTION OF ORGANIZATION MISSION: FORM 990, PART III,

INTERESTED IN ADVANCING CARE FOR PEOPLE WITH HEMOSTATIC AND THROMBOTIC

DISORDERS.

FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS:

STAGES OF THEIR CAREERS, INCLUDING: (1)THE STUDENT RESEARCH AWARD

AN 8-WEEK INTRODUCTION TO RESEARCH IN CLASSICAL HEMATOLOGY FOR (SRA)

UNDERGRADUATE, MEDICAL, AND DOCTORAL STUDENTS WORKING WITH AN

EXPERIENCED MENTOR; (2) THE CLINICAL SCHOLAR AWARD (CSA), A FOURTH AND

FINAL YEAR OF INTENSIVE CLINICAL TRAINING IN HEMOPHILIA AND RARE BLOOD

DISORDERS UNDER THE GUIDANCE OF AN EXPERIENCED MENTOR; (3) THE MENTORED

RESEARCH AWARD (MRA), A TWO-YEAR RESEARCH AWARD FOR EARLY-CAREER

INVESTIGATORS WORKING WITH AN EXPERIENCED MENTOR. THE MRA IS DESIGNED

TO PREPARE RECIPIENTS TO APPLY FOR A K-AWARD OR EQUIVALENT FROM THE

NATIONAL INSTITUTES OF HEALTH (NIH) TO FORMALLY LAUNCH THEIR RESEARCH

CAREERS IN ACADEMIC MEDICINE; AND (4) THE MID-CAREER RESEARCH AWARD,

TWO-YEAR AWARD FOR INVESTIGATORS WHO HAVE COMPLETED FELLOWSHIP OR

POST-DOCTORAL WORK AND NEED SUPPORT TO TRANSITION FROM MENTORED

RESEARCH TO FULLY-INDEPENDENT, INVESTIGATOR INITIATED RESEARCH GRANTS

FROM THE NIH OR OTHER NATIONAL SOURCES.

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ. 232211 10-28-22

Schedule O (Form 990) 2022

36

Name of the organization	HEMOSTASIS AND THROMBOSIS RESEARCH SOCIETY, INC.	Employer identification number 39–1796672
	SUCIEII, INC.	<u>39-1/900/2</u>

FORM 990, PART III, LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS:

HELD DURING THE THSNA SUMMIT IN CHICAGO, IL AND THE 2022 AMERICAN

SOCIETY FOR HEMATOLOGY (ASH) NATIONAL CONGRESS IN NEW ORLEANS, LA.

FORM 990, PART VI, SECTION A, LINE 6:

THERE IS ONE CLASS OF MEMBERSHIP. CLINICIANS AND PHYSICIAN-SCIENTISTS,

BASIC AND TRANSLATIONAL SCIENTISTS, EPIDEMIOLOGISTS, COAGULATION LABORATORY

PROFESSIONALS, AND ALLIED HEALTH CARE PROFESSIONALS INTERESTED IN THE

PURPOSE OF THE CORPORATION CAN JOIN HTRS.

FORM 990, PART VI, SECTION A, LINE 7A:

MEMBERS OF THE CORPORATION ELECT THE OFFICERS AND DIRECTORS.

FORM 990, PART VI, SECTION B, LINE 11B:

A COPY OF FORM 990 IS PROVIDED TO THE BOARD OF DIRECTORS FOR REVIEW PRIOR TO FILING.

FORM 990, PART V, LINE 2A

HEMOSTATIS AND THROMBOSIS RESEARCH SOCIETY, INC. LEASES EMPLOYEES FROM

A PROFESSIONAL EMPLOYMENT ORGANIZATION, VERSITI WISCONSIN, INC. THE

EMPLOYEES ARE CONSIDERED COMMON LAW EMPLOYEES OF HEMOSTATIS AND

THROMBOSIS RESEARCH SOCIETY, INC., HOWEVER, VERSITI WISCONSIN, INC. IS

THE EMPLOYER OF RECORD AND EMPLOYEES GET THEIR W2S FROM VERSITI

WISCONSIN, INC.

232212 10-28-22

FORM 990, PART VI, SECTION B, LINE 12C:

DIRECTORS AND OFFICERS ARE REQUIRED TO SUBMIT AN ANNUAL DISCLOSURE

37

Schedule O (Form 990) 2022

16000905 788028 13399.1AS01

2022.04020 HEMOSTASIS AND THROMBOSIS 13399.11

Schedule O (Form 990) 2022	Page <b>2</b>
Name of the organization HEMOSTASIS AND THROMBOSIS RESEARCH SOCIETY, INC.	Employer identification number 39-1796672
STATEMENT. ALL DISCLOSED FINANCIAL INTERESTS WILL BE SUBJE	СТ ТО
BOARD/COMMITTEE REVIEW. THE REVIEWING BOARD/COMMITTEE WILL	EXAMINE ALL
MATERIAL FACTS AND DISCUSS THE FINANCIAL INTEREST WITH THE	INTERESTED
PERSON (AS NECESSARY). IF PRESENT, THE INTERESTED PERSON S	HALL BE EXCUSED
FROM THE COMMITTEE MEETING AND THE REMAINING COMMITTEE MEM	BERS SHALL
DETERMINE WHETHER AN ACTUAL OR POTENTIAL CONFLICT OF INTER	ESTS EXISTS.
FORM 990, PART VI, SECTION B, LINE 15A:	
THE BOARD OF DIRECTORS ANNUALLY DETERMINES THE COMPENSATIO	N OF THE
EXECUTIVE DIRECTOR. A WAGE INCREASE IS SUGGESTED TO THE B	OARD BASED ON
FINANCIAL POSITION AND COMPENSATION OF SIMILARLY SIZED ORG	ANIZATIONS IN THE

AREA. THIS WAGE INCREASE IS THEN COMMUNICATED TO THE ORGANIZATION'S PEO TO BE IMPLEMENTED.

FORM 990, PART VI, SECTION C, LINE 19:

THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS AVAILABLE ON ITS WEBSITE AND ITS CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.

232212 10-28-22